Renovaro added Avram Miller, Leni Boeren, Ruud Hendriks, to the company’s board of directors
The three additions bring extensive financial backgrounds that will help as the company ventures into the new agreement with GEDiCube and Renovaro AI branding
Avram Miller believes that Renovaro Bioscience, combined with GEDiCube, has the key elements to play a significant role in transforming AI’s impact on medicine
Renovaro Biosciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene, and immunotherapy focused on solid tumors with short life expectancy, recently announced a definitive agreement to combine with the advanced AI Company GEDiCube Intl Ltd., rebranding as Renovaro AI. The company has also announced the addition of three new members to its board of directors – Avram Miller, Leni Boeren, and Ruud Hendriks.
Leni Boeren brings a 40-year career in the financial sector, with banking roles at Paribas and Rabobank. She has held several director-level positions at Amsterdam Exchanges and Euronext, the first pan-European stock and derivatives exchange resulting from the merger of exchanges in…
NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
PaxMedica (NASDAQ: PXMD), a pioneering biopharmaceutical company focused on advancing treatments for neurologic disorders, is working with leading financial services firm Bourne Partners. Bourne Partners specializes in the pharma, pharma services and consumer health spaces. According to the announcement, the collaboration is an important step in PaxMedica’s strategy to explore potential monetization of a Priority Review Voucher prior to filing the NDA for PAX-101 for the treatment of African Sleeping Sickness. Although PaxMedica has not yet been granted a PRV and there is no guarantee that one will be awarded, the company believes PAX-101 qualifies for the PRV program because African Sleeping Sickness is currently listed by the FDA as eligible for the program. The partnership with Bourne is representative of PaxMedica’s commitment to optimizing its valuable assets in its commitment to develop innovative healthcare solutions, enhance initiatives in the field of neurologic disorders, and expedite critical research and development efforts.
PaxMedica also reported its convertible note with Lind Global Partners II LP has decreased through a combination of cash and the issuance of approximately 0.34 million shares of common stock, effectively decreasing the remaining value of the note from $3.68 million to $2.27 million, enabling PaxMedica to potentially settle the debt earlier than initially anticipated. “We are excited to engage Bourne Partners to explore the structures that could potentially allow the company to monetize the value of a potential PRV,” said PaxMedica chairman and CEO Howard Weisman in the press release. “This represents our continued dedication to advancing healthcare solutions and underscores our commitment to driving meaningful change in the field of neurology.”
PaxMedica is a forward-looking, clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (“APT”) designed to address challenging neurologic disorders. The company’s scope encompasses a spectrum of conditions, from neurodevelopmental disorders, including autism spectrum disorder (“ASD”) to the debilitating myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”), marked by both physical and cognitive burdens. PaxMedica prioritizes the advancement and evaluation of its flagship program, PAX-101, an intravenous suramin formulation primarily focused on ASD treatment, while also broadening its clinical insights into potential applications for conditions such as ME/CFS. For more information about the company, visit www.PaxMedica.com.
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, will be presenting an oral presentation at the 12th World Congress on Itch (“WCI”); the event is scheduled for Nov. 5–7, 2023, in Miami. According to the announcement, the oral presentation is based on an abstract describing the phase 2 clinical study of investigational drug INM-755 cannabinol cream for the treatment of symptoms in patients with rare genetic skin disease called epidermolysis bullosa (“EB”). InMed Pharmaceuticals senior vice president of Clinical and Regulatory Affairs Alexandra Mancini will be presenting. The abstract title is “INM-755 Cannabinol Cream Demonstrates Anti-Itch Activity in Patients with Epidermolysis Bullosa.” Mancini’s presentation is scheduled to begin at 4:08 p.m. ET on Nov. 7. Designed to evaluate the safety of INM-755 CBN cream, the phase 2 within-patient, double-blind study gathered preliminary evidence of the cream’s efficacy in treating symptoms and healing wounds over a 28-day period in patients with EB. The data showed a positive indication of enhanced anti-itch activity for INM-755 cannabinol cream versus the control cream alone. A copy of the poster and other presentation materials will be on the company’s website following the event.
InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. The company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, please visit www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today shared an open letter to shareholders from CEO David Michery, providing updates on various matters and company initiatives. In the letter, Michery highlights several recent company accomplishments, including its commencement of Class 1 EV cargo vans on Nov. 1, 2023. “Over the past few months, the company has reached critical milestones towards accomplishing our ultimate goal to be a leader in the EV industry,” Michery stated in the letter. “We remain steadfastly dedicated to our employees, stakeholders and customers during this journey and thank you for your continued support of Mullen.”
Mullen is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen-GO Commercial Urban Delivery EV, Mullen Commercial Class 1-3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. For more information about the company, visit www.MullenUSA.com.
NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN
About GreenCarStocks
GreenCarStocks (“GCS”) is a specialized communications platform with a focus on electric vehicles (“EVs”) and the green energy sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled recognition and brand awareness. GCS is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from GreenCarStocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the GreenCarStocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Application showed an improvement of 50% in customer rewards program effectiveness for the same amount of budget
Italian fintech company Satispay anticipates that its internal teams will use the application weekly when the company transitions it into production
D-Wave’s suite of services is backed by two decades of quantum technology development and over ten years of customer feedback, which have been incorporated to create the industry’s first quantum computer designed for commercial business applications
D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services and the world’s first commercial supplier of quantum computers, recently announced that it is working with Satispay, the leading Italian fintech unicorn revolutionizing mobile payments, to build a quantum-hybrid application designed to optimize customer rewards initiatives (https://ibn.fm/u15OM).
Using D-Wave’s constrained quadratic model (“CQM”) hybrid solver, the application showed an improvement of 50% in customer rewards programs for the same amount of budget – identifying more effective approaches to Satispay’s rewards programs and the goal of increasing membership of its…
NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
Forward-Looking Statements
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding Satispay’s plans to transition the application to production, the expected usage of the application by Satispay’s internal teams, and the potential impact of the application once in production. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the usage of the application by Satispay’s internal teams and the continued positive impact of the application once in production; general economic conditions and other risks; the company’s ability to expand its customer base and the customer adoption of the company’s solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of D-Wave’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of the company’s products; the effects of competition on the company’s business; the risk that D-Wave will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the company may never achieve or sustain profitability; the risk that the company is unable to secure or protect its intellectual property; volatility in the price of the company’s securities; the risk that the company’s securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Rat populations have created concerns for centuries because of their potential to be a vector for diseases, their destruction of infrastructure, and their consumption or spoilage of stored food supplies
Arizona-based SenesTech Inc. is now introducing its new Evolve(TM) Soft Bait as a companion to its patented ContraPest(R) liquid product as means of shifting rodent control methods from lethal poisons to preventative birth control formulations, with Evolve(TM) Soft Bait representing a big step into a major new market
The company recently discussed its operation and plans for the near future during a webcast presentation as part of Lytham Partners’ Fall 2023 Investor Conference
SenesTech has produced successes during testing at West Coast and East Coast poultry farms, and has achieved new client agreements that extend to the countries of Maldives and South Africa
Rodent control innovator SenesTech (NASDAQ: SNES) is delivering a new method of administering its unique, patented contraceptive technology that serves as a form of birth control in both male and female rats, making SenesTech’s solution to the rat population more readily accessible and appealing to pest management companies as well as consumers who prefer non-liquid baits.
The company’s new trademarked Evolve(TM) Soft Bait is an important non-liquid addition to SenesTech’s portfolio, which includes the liquid ContraPest(R) bait brand that has been its flagship product (https://ibn.fm/KhoQm). Since non-liquid forms of control products are preferred by…
NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that Catherine Vaczy, its EVP, general counsel and chief strategy officer, will be providing an overview of the company’s gene therapies for cancer and diabetes at the upcoming BIO-Europe 2023 Conference taking place in Munich, Germany. Vaczy’s presentation is slated to begin at 4:45 p.m UTC on Tuesday, Nov. 7, 2023. Several members of Genprex’s executive leadership team will be in attendance at BIO-Europe 2023. Those interested in meeting Genprex management during the event should request a meeting through the conference portal or reach out to investor relations at [email protected].
Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its systemic, non-viral ONCOPREX(R) Nanoparticle Delivery System, which encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The company’s lead product candidate, REQORSA(R) (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (“NSCLC”) and small cell lung cancer (“SCLC”). Each of Genprex’s three lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and its SCLC program has received an FDA Orphan Drug Designation. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an adeno-associated virus (“AAV”) vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-003 for type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. For more information, visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
The UK’s criminal justice department recently announced that domestic abusers leaving prison will be wearing electronic monitoring tags for better victim protection
Up to 500 offenders will be forced to wear GPS and curfew tags to monitor their movements, with those who breach the stipulated license conditions being returned to prison
This move by the UK validates digital monitoring solutions such as SuperCom’s Electronic Monitoring (“EM”) products
It also shows the technology’s viability in solving emerging issues while also validating SuperCom’s research and development efforts as targeting an active and growing world market
SuperCom (NASDAQ: SPCB), a global provider of traditional and digital identity solutions offering advanced safety, identification, and security products and solutions to governments, is constantly pushing the envelope with innovation and exploring new markets for its products. This ambition has been driven by its mission and commitment to “creating safer communities”. More nations globally are beginning to realize the need for more advanced technologies to manage offender populations, representing a significant growth opportunity for SuperCom.
In September 2023, the UK’s criminal justice department announced that domestic abusers leaving prison would wear electronic monitoring tags to offer better victim protection. The plan, which will first launch in East and West Midlands, will see up to 500 offenders forced to wear GPS or curfew tags to monitor their…
NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
NetworkNewsWire Editorial Coverage: GLP-1 agonists have become incredibly popular obesity drugs, reshaping the standard of care as people increasingly turn to the new class of drugs in lieu of conventional weight-loss procedures. There is a growing body of clinical evidence showing GLP-1 agonists safely control blood sugar (glucose) levels and deliver tremendous positive outcomes, such as a recent New England Journal of Medicine study reporting weight loss of 49 to 52 pounds. As good as GLP-1 agonist are, they can get better, which is part of the mission of Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), a global innovator in drug-delivery platforms. The company started diabetes-related formal studies in 2022 evaluating its DehydraTECH(TM) platform, which showed lower blood-sugar levels and decreased body weight. This compelling data is undergirding the next phase of research, new human and animal studies for the purpose of demonstrating DehydraTECH processing can make GLP-1 drugs even more effective and more accessible. Positive developments on DehydraTECH could catch the attention of companies dedicated to developing drugs that support better health— companies such as Johnson & Johnson (NYSE: JNJ), Sanofi (NYSE: SNY), Amgen (NASDAQ: AMGN), and Novartis AG (NYSE: NVS)…
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, is reporting on its financial results for the third quarter ended Sept. 30, 2023; the report also included key business updates. Financial numbers to note in the report include R&D expenses of $1.13 million compared to $1.19 million for the same quarter in 2022; marketing, general and administrative expenses for the quarter totaled $0.97 million compared to $0.96 million for the three months ended Sept. 30, 2022; total operating expenses for the quarter came in at $2.1 million with financial income for the three months totaling $5.2 million and net income loss for Q3 2023 at $3.1 million, down from the $4.7 million loss reported for Q3 2022. The report also noted that as of Sept. 30, 2023, Scinai had cash and cash equivalents of $6.4 million as compared to $14.2 million as of Dec. 31, 2022. Corporate highlights cited included a strategic pivot, which entailed rebranding as Scinai Immunotherapeutics, and the raising of $1.33 million through a registered direct offering with H.C. Wainwright & Co. acting as placement agent. The report also noted that the company’s primary creditor, the European Investment Bank (“EIB”), is considering favorably adjusting the terms of its financial facility contract with Scinai in order to extend the cash runway and address a NASDAQ minimum shareholders’ equity compliance issue.
The announcement said that formal feedback from EIB management regarding a definitive amendment to the facility could come as soon as this month. In addition, this month the company closed its first contract to provide CDMO services and is in advanced contract discussions with other potential clients. The report also noted that Scinai is aggressively advancing the NanoAb preclinical development with meaningful ex vivo results anticipated in Q4 2023; Scinai is also pursuing a strategic partnership for its COVID-19 self-administered inhaled NanoAb, which showed highly promising in vivo results in animals as both a therapeutic and prophylactic treatment. “I thank the EIB for their ongoing support and cooperation,” said Scinai Immunotherapeutics CEO Amir Reichman in the press release. “As the lending arm of the European Union, the EIB’s mission includes providing financing to support medical research and improve healthcare. The anticipated adjustment of our financial facility agreement with the EIB will provide much-needed relief to our financial position, thereby helping to clear the path towards developing Scinai into a company that provides significant benefits to patients and investors.”
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing along with highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody, or NanoAb, pipeline targeting diseases with large unmet medical needs. For more information, visit the company’s website at www.Scinai.com.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, announced that it will hold a conference call on Tuesday, Nov. 14, 2023, at 4:30 p.m. Eastern Time to discuss its results for the third quarter ended Sept. 30, 2023. The company will also review recent announcements, ongoing initiatives and anticipated 2024 milestones. HeartBeam CEO and Founder Branislav Vajdic, PhD, President Robert Eno and CFO Richard Brounstein will host the call, followed by a question-and-answer period. Accompanying the conference call will be a presentation, which can be viewed during the webcast or accessed via the investor relations section of the company’s website. Interested parties should visit https://ibn.fm/MjjBw to access the webcast and dial 1-877-704-4453 or 1-201-389-0920 (international) and enter conference code 13741784 to join the call. A telephone replay will be available approximately three hours after the call as detailed in the announcement.
HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform intended for patient use at home. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to assess their cardiac symptoms quickly and easily, so care can be expedited, if required. HeartBeam AIMIGo(TM) is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms. By collecting 3D signals of the heart’s electrical activity, HeartBeam AIMIGo has the potential to provide unparalleled data for the development of AI algorithms. HeartBeam AIMIGo has not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the USA or other geographies. For more information, visit www.HeartBeam.com.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
PaxMedica (NASDAQ: PXMD), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological disorders, today announced the successful acquisition of certain suramin research assets from Rediscovery Life Sciences (“RLS”). The assets were previously dedicated to the study of suramin’s potential efficacy in treating acute kidney injury resulting from chronic kidney disease. According to the announcement, the newly acquired data from RLS will play a crucial role in bolstering PaxMedica’s ongoing efforts to support the submission for the approval of PAX-101, specifically for the treatment of African sleeping sickness caused by the Trypanosoma brucei rhodesiense parasite. “Acquiring the research assets from Rediscovery Life Sciences marks a significant leap forward in our journey to expedite the NDA submission process for PAX-101,” said Howard Weisman, chairman and CEO of PaxMedica, in a recent statement regarding the significance of the acquisition. “This valuable addition of data will significantly contribute to our mission of delivering effective and life-saving treatments for human African sleeping sickness.”
PaxMedica is a forward-looking clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (“APT”) designed to address challenging neurologic disorders. Its scope encompasses a spectrum of conditions, from neurodevelopmental disorders, including autism spectrum disorder (“ASD”), to the debilitating myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”), marked by both physical and cognitive burdens. PaxMedica prioritizes the advancement and evaluation of its flagship program, PAX-101—an intravenous suramin formulation—primarily focused on ASD treatment, while also broadening clinical insights into its potential applications for conditions such as ME/CFS. For more information, visit www.PaxMedica.com.
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Freight Technologies (“Fr8Tech”) is a North American transportation logistic technology company
The company is keen on simplifying cross-border shipping in the U.S.-Canada-Mexico Agreement (“USCMA”) region by capitalizing on the advanced capabilities of its Fr8App platform
Fr8App seamlessly connects shippers in the U.S., Canada, and Mexico with an extensive network of reliable carriers and drivers
Through Fr8App, Fr8Tech is participating in the trucking and freight market’s ongoing paradigm shift, which has seen more and more shippers opt for brokerage services instead of dealing directly with carriers
Freight brokers are handling over 20% of all trucking freight, up from 6% in 2000
Freight brokers are changing the face of the trucking industry, upending decades-old preferences that previously forced them to operate on the fringes. Brokers now handle over 20% of all trucking freight, up from 6% in 2000. This growth is attributed partly to brokerages’ investments in customer service and technology, which enabled them to offer a “more compelling product” than asset-based carriers and take on a “greater role in routing guides,” according to a recent article (https://ibn.fm/zdexO). As a result, brokers now handle higher quality cargo than in 2000 and are often assigned highly desirable, carrier-friendly freight.
The growth is also due to a number of other factors, chief among them being the fact that brokerages have built extensive databases of reliable carriers and frequent shippers. This means that shippers can lean on brokers for reliable carriers who will ensure their loads are shipped and delivered on…
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
SuperCom Ltd. (NASDAQ: SPCB), a global provider of secured solutions for the e-Government, IoT and cybersecurity sectors, today announced, together with its local partner, the receipt of a third order by Romania’s Ministry of Interior, further extending the successful partnership and reinforcing their commitment to Romania’s National Electronic Monitoring (“EM”) Project. According to the announcement, the order is valued at approximately $3.4 million and is anticipated to be delivered by the end of the fourth quarter of 2023. “We are excited to extend our collaboration with the Romanian government on this pivotal initiative. The recent order, valued at $3.4 million, underscores the caliber of our technology and the unwavering trust our clients have in SuperCom,” said Ordan Trabelsi, president and CEO of SuperCom. “The Romanian Project is progressing as planned. Thanks to our expert team and state-of-the-art technology, we’ve ensured flawless execution, consistently meeting and surpassing stakeholder expectations. This latest order reinforces our status as a global frontrunner in electronic monitoring solutions. At SuperCom, we are dedicated to not only achieving excellent outcomes but also building enduring relationships with governments across the globe.”
Since 1988, SuperCom has been a global provider of traditional and digital identity solutions, providing advanced safety, identification and security solutions to governments and organizations, both private and public, throughout the world. Through its proprietary e-Government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance and border control services, SuperCom has inspired governments and national agencies to design and issue secure multi-ID documents and robust digital identity solutions to its citizens and visitors. SuperCom offers a unique all-in-one field-proven RFID & mobile technology and product suite, accompanied by advanced complementary services for various industries including healthcare and homecare, security and safety, community public safety, law enforcement, electronic monitoring, livestock monitoring, and building and access automation. For more information about the company, visit www.Supercom.com.
NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms, has released information regarding its 1-for-17 reverse stock split. According to the announcement, as a result of the reverse stock split of PaxMedica’s common stock that became effective at 8:03 a.m. ET today, the company’s common stock will begin trading on a split-adjusted basis tomorrow, Oct. 31, 2023, when the market opens. The company noted that its common stock will continue to trade under the existing trading symbol PXMD. “As a result of the reverse stock split, each 17 presplit shares of common stock outstanding were automatically combined and converted into one issued and outstanding share of common stock,” the company stated in the press release. “No fractional shares of common stock were issued to any stockholders in connection with the reverse stock split. Holders of record who would otherwise have been entitled to receive a fractional share received a number of shares rounded up to the next whole share in lieu of fractional shares.”
PaxMedica is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (“ASD”) to myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”), a debilitating physical and cognitive disorder. One of PaxMedica’s primary points of focus is the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and the advancing the clinical understanding of using that agent against other disorders such as ME/CFS. For more information about the company, visit www.PaxMedica.com.
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, will be attending and participating in BIO-Europe, one of Europe’s premier pharmaceutical industry partnering events. The event is slated for Nov. 6–8, 2023, in Munich, Germany. According to the announcement, Scinai will showcase both its CDMO services, marketed under the brand Scinai Bioservices, and its in-house nanosized VHH antibody-based therapeutics pipeline. In addition, management will be available to meet with potential partners and clients. Scinai offers a state-of-the-art manufacturing facility for biopharmaceutical products as well as biologic drugs process development and scale-up for protein-based drugs; the company also provides analytical method development for QC testing and cGMP manufacturing. In addition, the company’s in-house R&D program specializes in developing, manufacturing and commercializing I&I biological products targeting the treatment of autoimmune and infectious diseases.
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing along with highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody, or NanoAb, pipeline targeting diseases with large unmet medical needs. For more information, visit the company’s website at www.Scinai.com.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
SenesTech, a rodent fertility control expert, just announced the launch of its Evolve(TM) Soft Bait, representing an innovative, patent pending, minimum risk alternative treatment to reduce fertility in rats
This product adds to the company’s growing line of pest control solutions, such as ContraPest(R), a highly palatable liquid contraceptive bait
SenesTech’s management has lauded this milestone, noting how the product, with its non-liquid form, will dramatically increase its addressable market
The company plans to market it to professionals as well as directly to consumers through e-commerce and big-box stores
SenesTech (NASDAQ: SNES), a rodent fertility control expert and the inventor of the only EPA-registered contraceptive for male and female rats, just announced the launch of its Evolve(TM) Soft Bait (“Evolve”), a minimum-risk solution in a new form, designed to reduce fertility in rats. As a potential solution to the root cause of pest problems – rats’ ability to rapidly reproduce – Evolve offers an effective product in a format that is familiar to pest control professionals and at a price that is comparable to traditional rodenticides. Results can be seen in as little as four to six weeks (https://ibn.fm/yS388).
Evolve(TM) adds to SenesTech’s growing line of pest control solutions, such as ContraPest(R), a highly palatable liquid rat contraceptive bait. Like the company’s other products, Evolve(TM) promises to offer a long-term solution to pest problems, effective fertility control, and a user-friendly format perfect for…
NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
Longeveron, a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, reported positive top-line results from its CLEAR MIND Phase 2a human clinical trial
The study, which explored Lomecel-B(TM)’s effects on mild Alzheimer’s disease, met the primary endpoint of safety on statistical and medical assessment
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, just announced positive top-line results from its CLEAR MIND Phase 2a clinical trial for treating mild Alzheimer’s disease. Most notably, the primary endpoint of safety was met based on statistical and medical assessment, with only one Serious Adverse Event (“SAE”) reported on each Lomecel-B(TM) group in what Dr. Jeffrey Cummings, MD, Vice Chair of Research, UNLV Department of Brain Health, described as “Encouraging results” (https://ibn.fm/BNOjU).
This study was designed to explore Lomecel-B(TM)’s effects on mild Alzheimer’s disease. Dubbed the CLEAR MIND trial, this randomized, double-blinded, placebo-controlled Phase 2a trial included 50 patients aged between 60 and 85 years diagnosed with mild Alzheimer’s disease. The study was…
NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at http://ibn.fm/LGVN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
NetworkNewsWire Editorial Coverage: The prestigious New England Journal of Medicine recently published results of a large study of 2,539 adults wherein weight loss of 49 to 52 pounds was a common outcome. With more than 37 million Americans suffering from diabetes, and with obesity at epidemic levels, it’s little wonder that millions of people are singing their praises of the new class of drugs responsible for these outrageously positive outcomes. GLP-1 agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with type 2 diabetes but are also helping treat obesity. Seems everyone is excited about controlling blood sugar and easily losing weight. But there may be an even better avenue to increased effectiveness and better outcomes. Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), a global innovator in drug-delivery platforms, began diabetes-related formal studies last year with its DehydraTECH(TM) platform, which showed reduced blood-sugar levels and lowered body weight. With such encouraging early results, Lexaria is planning to launch new human and animal studies to examine whether DehydraTECH processing can make GLP-1 drugs such as semaglutide even better. Lexaria’s heavily-patented DehydraTECH drug delivery technology might improve bioavailability, lower costs, and enhance tolerability, weight-loss potential and management of diabetes and other health conditions. DehydraTECH may become a game changer in the multibillion-dollar GLP-1 drug market and could potentially lead to a collaboration with a dominant player in the space, such as Novo Nordisk (NYSE: NVO), Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), or AstraZeneca PLC (NASDAQ: AZN).
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.
Clene is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases like ALS
In 2019, Clene’s drug candidate, CNM-Au8(R), was selected for the HEALEY ALS Platform Trial, with enrollment commencing in the summer of 2020
Over the years since, Clene has consistently released additional data from the Trial, most recently reporting significant long-term survival improvement among patients treated with CNM-Au8 compared to PRO-ACT historical controls
The company also announced the publication of a peer-reviewed study in the nanotechnology-focused journal Small; the study describes CNM-Au8’s mechanism of action
Clene received a $45.1 million NINDS grant to support an Expanded Access Protocol (“EAP”) program and study for CNM-Au8 in ALS
Amyotrophic lateral sclerosis (“ALS”), or Lou Gehrig’s disease, is a progressive and degenerative neuromuscular disease that destroys nerve cells known as motor neurons, which control voluntary muscle movement (https://ibn.fm/bgJGu). A fatal neurological disorder, ALS lowers the life expectancy of patients to two to five years post-diagnosis, although some patients may live longer, as was the case with the late Stephen Hawking, who lived with ALS for more than five decades (https://ibn.fm/v6LIz).
The Centers for Disease Control and Prevention (“CDC”) estimated that more than 31,000 patients were living with ALS in 2017 (https://ibn.fm/Vdee8), with a subsequent study calculating the 2017 prevalence of ALS in the adult U.S. population arriving at an age-adjusted prevalence of between 5.5 and 9.9 per…
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Electronic security solutions innovator SuperCom Ltd. is reporting a number of successes in its business operation for providing technology and service to criminal justice programs
SuperCom reported last month that it has acquired a new contract with a California agency that will run through 2026 for providing alcohol monitoring that leverages smartphone technology
SuperCom provides services on a global scale, including Croatia, Sweden, Finland, and Romania, within its arena of operation
In July, the company reported a 141 percent record increase in its year-over-year quarterly revenues, the fourth consecutive period in which it saw high year-over-year revenue growth
Electronic-monitoring security solutions innovator SuperCom (NASDAQ: SPCB) is celebrating a new contract to provide alcohol monitoring technology and service for a client in the California criminal justice system.
“This contract marks another strong achievement, building on our track record of securing numerous new electronic monitoring contracts in the United States and Europe,” SuperCom CEO and President Ordan Trabelsi stated in a news release about the…
NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
InMed Pharmaceuticals (NASDAQ: INM) is a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs. The company today announced that it has closed its offering for the issuance and sale of 3,012,049 pre-funded warrants and preferred investment options to purchase up to an aggregate of 3,012,049 common shares, at a purchase price of $0.83 per pre-funded and associated preferred investment option, in a private placement priced at-the-market under Nasdaq rules. Per a previously announced definitive agreement with respect to certain of its outstanding preferred investment options issued in November 2022 and exercisable for 3,272,733 common shares, in the aggregate, the holders of such outstanding preferred investment options have exercised such investment options for cash at a reduced exercise price of $0.83 per share, in exchange for unregistered new preferred investment options to purchase up to 6,545,466 common shares. InMed secured approximately $5.2 million in aggregate gross proceeds, from which it intends to use the net proceeds to continue pipeline development of its pharmaceutical drug candidates, support commercial sales of rare cannabinoids through its subsidiary BayMedica LLC, and for general working capital purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the offerings.
InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. The company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, visit www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company, announced that its groundbreaking research will be published in the “Annals of General Psychiatry,” an internationally recognized scientific psychiatry publication. The research was reported in a manuscript titled “Randomized clinical trial of low-dose suramin intravenous infusions for treatment of autism spectrum disorder,” which will be published by the psychiatry publication. Written by PaxMedica chief medical officer Dr. David Hough, MD, along with nine coauthors, the article reports on the potential of monthly suramin intravenous infusions as a safe and potentially efficacious treatment for the core symptoms of autism spectrum disorder (“ASD”). Coauthors of the article include Alice Mao, MD; Michael Aman, PhD; Reymundo Lozano, MD, MS; Constance Smith-Hicks, MD, PhD; Veronica Martinez-Cerdeno, PhD; Michael Derby; Zachary Rome; Miel Malan, MD; and Robert Findling, MD. An open access journal emphasizing a biopsychosocial approach to illness and health, the “Annals of General Psychiatry” supports the principles of evidence-based medicine, further validating the significance of this research. “The acceptance of this manuscript represents a significant milestone in PaxMedica’s continued dedication to pioneering innovative treatments for autism spectrum disorder,” said PaxMedia chief medical officer Dr. David Hough in the press release. “We are honored to contribute to the field of psychiatry with this significant research, underscoring our commitment to advancing the understanding and treatment of ASD.”
PaxMedica is a forward-looking, clinical-stage biopharmaceutical firm specializing in cutting-edge, anti-purinergic drug therapies (“APT”) designed to address challenging neurologic disorders. Its scope encompasses a spectrum of conditions, from neurodevelopmental disorders, including autism spectrum disorder (“ASD”) to the debilitating myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”), marked by both physical and cognitive burdens. PaxMedica prioritizes the advancement and evaluation of its flagship program, PAX-101 — an intravenous suramin formulation — primarily focused on ASD treatment, while also broadening clinical insights into its potential applications for conditions such as ME/CFS. For more information about the company, visit www.PaxMedica.com.
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Scinai will exhibit at the upcoming CPHI Barcelona event, showcasing its CDMO services
The company expanded into the CDMO business earlier this year, operating under the banner Scinai Bioservices
Scinai’s boutique end-to-end CDMO business division serves pharmaceutical, biotech, and alternative protein food tech companies with pilot and clinical process development and cGMP manufacturing
Scinai intends to serve small biotech companies who require CDMO services with superior value compared to large, multinational CDMO companies
Scinai will also exhibit at the upcoming BIO-Europe conference in Munich
Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, will be showcasing its Contract Development and Manufacturing Organization (“CDMO”) services at CPHI Barcelona, a premier three-day event that brings together pharmaceutical professionals, industry leaders, and businesses to advance human health. The event is scheduled for October 24 to 26, 2023, at Fira Barcelona Gran Via, Spain (https://ibn.fm/veEp4).
The company has been allocated Booth 81HA11, where potential partners and clients of the company’s CDMO service will get to meet several members of Scinai’s executive leadership team. Registered attendees may also request one-on-one meetings through the…
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) is a technology company offering its custom-developed Fr8App, an industry-leading freight-matching platform powered by AI and machine-learning and providing a real-time portal for B2B cross-border shipping and domestic shipping within the USMCA region. The company today announced a significant achievement with the recent success of securing an RFQ (Request for Quotation) from a leading global pharmaceutical giant. According to the announcement, the prestigious pharmaceutical conglomerate, renowned for its unwavering commitment to global health and life-changing innovations, has chosen Fr8App as its trusted partner for a crucial logistics operation. “We are incredibly proud and honored to have been chosen to undertake this vital logistics operation,” said Javier Selgas, CEO of Fr8Tech. “This achievement represents a significant step in our mission to provide world-class logistics services, especially in the pharmaceutical industry, where precision and reliability are paramount. Our team is ready and excited to meet the high expectations of our esteemed client.”
Freight Technologies (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process. Its wholly owned subsidiary, Freight App Inc. (“Fr8App”), is a B2B cross-border shipping marketplace in the USMCA region powered by AI and machine learning. Focused on making shipping transparent and efficient, Fr8App provides carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road (“OTR”) shipping. Fr8App uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via innovative technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management, and committed capacity solutions. The company is headquartered in Houston, Texas. For more information, please visit Fr8Technologies.com.
NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software and services as well as the world’s first commercial supplier of quantum computers, has extended its relationship with QuantumBasel. In addition, according to the announcement, D-Wave is planning to open a European office on the QuantumBasel campus to support the companies’ collaboration in fast tracking the commercialization of quantum computing in the region and facilitating increased development of near-term quantum applications for businesses, governments and researchers.
QuantumBasel is Switzerland’s first quantum hub for commercial use embedded in the uptownBasel innovation campus, which serves as a global hub for Industry 4.0, seamlessly connected to the world while firmly rooted in Basel, Switzerland. Among D-Wave’s annealing quantum computing solutions is the Advantage(TM) system, a fifth-generation annealing quantum system that features more than 5,000 qubits and 15-way connectivity.
“QuantumBasel and D-Wave share a vision of solving the world’s most complex problems for the betterment of industry and society,” said D-Wave Quantum CEO Dr. Alan Baratz in the press release. “Today’s announcement reflects strong progress toward achieving that mission, as joint customers are quickly realizing the near-term advantage of D-Wave’s quantum technology. Through our collaboration and now our plans for a European office presence, we anticipate accelerated momentum for quantum and quantum-hybrid applications moving into production and fueling operations.”
D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers — and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s customers include Volkswagen, Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California and Los Alamos National Laboratory. For more information about the company, please visit www.DWaveSys.com.
Forward-Looking Statements
Certain statements in this newsbreak are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this newsbreak include, but are not limited to, statements regarding D-Wave’s plans to open a European office on the QuantumBasel campus and the potential results of the collaboration between D-Wave and uptownBasel. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including general economic conditions and other risks; our ability to expand our customer base and the customer adoption of our solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of our business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of our products; the effects of competition on our business; the risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect our intellectual property; volatility in the price of our securities; the risk that our securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this newsbreak in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.
NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
About AINewsWire
AINewsWire (“AINW”) is a specialized communications platform with a focus on the latest advancements in artificial intelligence (“AI”), including the technologies, trends and trailblazers driving innovation forward. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, AINW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, AINW brings its clients unparalleled recognition and brand awareness.
AINW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from AINewsWire, text “AI” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the AINewsWire website applicable to all content provided by AINW, wherever published or re-published: https://www.AINewsWire.com/Disclaimer
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, was notified by the NASDAQ Hearings Panel that its request to continue listing on the NASDAQ capital market has been granted with two conditions. Those conditions call for the company to maintain a closing bid price of $1 per share for 20 consecutive trading sessions on or before Jan. 22, 2024, and hold an annual shareholder meeting on or before March 8, 2024. According to the announcement, the company held a meeting on Aug. 3, 2023, where proposals were approved by shareholders, but shareholders did not have an opportunity to discuss company affairs with management at the meeting; the upcoming combined 2023 and 2024 annual meeting must include that opportunity in order to be compliant. “I am pleased NASDAQ gave the company this opportunity to continue implementing its business plan,” said Mullen Automotive CEO and share David Michery in the press release. “We are diligently working to regain and maintain compliance with NASDAQ’s continued listing requirements.”
Mullen Automotive is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover; the Mullen I-GO Commercial Urban Delivery EV; the Mullen commercial class 1–3 EVs; and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and class 4–6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of all Electric Last Mile Solutions (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. To learn more about the company, visit www.MullenUSA.com.
NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN
About GreenCarStocks
GreenCarStocks (“GCS”) is a specialized communications platform with a focus on electric vehicles (“EVs”) and the green energy sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled recognition and brand awareness. GCS is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from GreenCarStocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the GreenCarStocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
A recent Fox Business article discussed pest control company Orkin’s annual ranking of the “Top 50 Rattiest Cities,” where Chicago continues to top the list, followed by Los Angeles, New York City, Washington, D.C., and San Francisco. Rankings are based on the number of new rodent services showcasing the demand and efforts that residents and businesses of the top cities have taken to treat rodent issues. Among these are strategies such as cutting off rats’ food sources and developing new technologies to detect and exterminate rat populations. As an expert in animal fertility control and the inventor of the only EPA-registered contraceptive for male and female rats, SenesTech (NASDAQ: SNES) brings a sustainable and effective solution. Its ContraPest(R) and Evolve(TM) products fit seamlessly into all pest management programs, humanely managing animal population through fertility control.
SenesTech is an expert in animal fertility control. The company’s passion is to create a healthy environment by better controlling animal pest populations. Keeping an inescapable truth in mind—that two rats and their descendants can be responsible for the birth of up to 15,000 pups after a year—SenesTech invented ContraPest(R), the only U.S. EPA registered contraceptive for male and female rats, and Evolve(TM) minimum risk soft bait. Its products fit seamlessly into all integrated pest management programs, greatly improving the overall goal of effective pest management. SenesTech strives for clean cities, efficient businesses and happy households – with a product designed to be effective and sustainable. The company is committed to improving the health of the world by humanely managing animal populations through fertility control. For more information about the company, visit www.SenesTech.com.
NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Lexaria has continuously taken steps to protect its intellectual property internationally to safeguard the applicability of its patented DehydraTECH(TM) technology across the globe
The company recently announced that it had received two new Canadian patents, increasing to 37 the number of granted patents in its intellectual property (“IP”) portfolio
Lexaria has filed tens of patent applications in multiple jurisdictions that are considered to have the highest commercial potential
The company continues to investigate opportunities that could culminate in expansions of and additions to its intellectual property portfolio and is also filing new patent applications for discoveries that arise from its R&D programs
Lexaria Bioscience (NASDAQ: LEXX) is a global innovator and biotechnology company focused on developing technology that enhances the bioavailability of multiple fat-soluble active molecules and active pharmaceutical ingredients (“APIs”). The company’s flagship technology is the patented DehydraTECH(TM) drug delivery technology, which combines fat-soluble (lipophilic) molecules or APIs with specific fatty acids and carrier compounds, improving properties such as the speed of onset, brain absorption, and bioavailability.
The company has continuously worked on DehydraTECH since 2014, with these efforts expanding the technology’s potential area of impact, both geographically and by sector. For instance, thanks to its extensive research and development (“R&D”), the company has identified viable commercial…
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CBDWire
CBDWire (“CBDW”) is a specialized communications platform with a focus on CBD related news and updates in the cannabidiol (“CBD”) sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled recognition and brand awareness.
CBDW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CBDWire, text “CBDWire” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer
InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, has entered into a definitive agreement for the issue and sale of more than 3 million common shares, or prefunded warrants in lieu thereof. Specifically, the company agreed to a private placement of 3,012,049 common shares priced at $0.83 per share. In addition, the company entered an agreement for an associated preferred investment option as well as a definitive agreement regarding specific outstanding preferred investment options issued in November 2022. The announcement outlines specifics of the agreement. The company also stated that the preferred investment option to be issued will be exercisable immediately upon issuance; exercise price for the offerings will be $0.83 per share, with an expiration date five and one-half years from the date of issuance. InMed Pharmaceuticals is projected to receive approximately $5.2 million in net proceeds from the offerings, before standard deductions and expenses; the offerings should close on or about Oct. 26, 2023, subject to customary closing conditions being met. InMed Pharmaceuticals anticipates using the net proceeds to continue pipeline development of its pharmaceutical drug candidates and to fund commercial sales of rare cannabinoids. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings.
InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. The company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, please visit www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM
About TinyGems
TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software and services, has announced plans to report on its third-quarter financial results for the period ended Sept. 30, 2023. The company will issue its third quarter earnings press release before market opens on Nov. 9, 2023. In addition, D-Wave Quantum CEO Alan Baratz and CFO John Markovich will host a conference call on the same day; the call will begin at 8 a.m. ET. During the call, company officials will discuss D-Wave Quantum financial results as well as its business outlook. Those interested can access by call by dialing 1-800-908-9179 (domestic) or 1-312-281-1211 (international).
D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers — and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology is being used by some of the world’s most advanced organizations, including Volkswagen, Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California and Los Alamos National Laboratory. For more information about the company, please visit www.DWaveSys.com.
Forward-Looking Statements
Certain statements in this newsbreak are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this newsbreak include, but are not limited to, statements regarding the timing of the company’s release of financial results and the associated conference call. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including general economic conditions and other risks; our ability to expand our customer base and the customer adoption of our solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of our business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of our products; the effects of competition on our business; the risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect our intellectual property; volatility in the price of our securities; the risk that our securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this newsbreak in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.”
NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
About AINewsWire
AINewsWire (“AINW”) is a specialized communications platform with a focus on the latest advancements in artificial intelligence (“AI”), including the technologies, trends and trailblazers driving innovation forward. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, AINW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, AINW brings its clients unparalleled recognition and brand awareness.
AINW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from AINewsWire, text “AI” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the AINewsWire website applicable to all content provided by AINW, wherever published or re-published: https://www.AINewsWire.com/Disclaimer
InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced its selection of a lead Alzheimer’s disease drug candidate, named INM-901, following positive results from several proof-of-concept studies in a validated Alzheimer’s treatment model. InMed will be advancing cannabinoid analog INM-901 in its pharmaceutical drug development program. “The most recent studies of INM-901 demonstrate promising disease-modifying effects in an Alzheimer’s disease treatment model,” said Dr. Eric Hsu, InMed’s SVP of preclinical research and development. “We are optimistic that the next stage of studies will continue to show how this cannabinoid analog can improve neuronal function, a potential breakthrough in Alzheimer’s treatment. Alzheimer’s disease patients have had limited treatment options until recently and while there have been advancements in understanding disease pathology, there are major limitations to current therapies. There remains a huge unmet medical need for this progressive disease that takes a major toll on patients and their families.”
InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. The company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, visit www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, is featured in a recent NetworkNewsAudio (“NNA”) broadcast. The segment focuses on the company’s most recent announcement of its topline results from the CLEAR Mind phase 2a clinical trial of LGVN’s Lomecel-B(TM) for the treatment of mild Alzheimer’s disease. According to the segment, the Lomecel-B study met its primary safety endpoint and is supported by lack of deterioration in cognitive or atrophy signals. The encouraging results will be used as a foundation for further studies, the company noted. NNA segments are designed to bring a company additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points.
The audio news release covers Longeveron’s recent news regarding positive top-line results from its phase 2a trial of its investigational product Lomecel-B(TM) for the treatment of mild Alzheimer’s disease. “We believe these results provide important validation of both the safety and therapeutic potential of Lomecel-B in the treatment of Alzheimer’s disease and provide a robust foundation for additional clinical trials in this and other indications,” said Longeveron CEO Wa’el Hashad in the news release. “We look forward to announcing additional biomarker data from this trial, anticipated to be later this month, which may further characterize the clinical effects of Lomecel-B in this study population. With our phase 2 ELPIS II trial in HLHS moving toward anticipated completion in 2024, and our phase 2 program in Aging-Related Frailty progressing in Japan as well, we look forward to meaningful milestones in the near term and to fully realizing the therapeutic potential of Lomecel-B.”
Longeveron is a clinical-stage, biotechnology company developing regenerative medicines to address unmet medical needs. The company’s lead investigational product is Lomecel-B(TM), an allogeneic medicinal signaling cell (“MSC”) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action encompassing provascular, proregenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently advancing Lomecel-B through clinical trials in three indications: hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty. To learn more about the company, visit www.Longeveron.com.
NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at https://ibn.fm/LGVN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Clene’s wholly-owned subsidiary, Clene Nanomedicine Inc., in collaboration with Columbia University and Synapticure, has been awarded a four-year grant totaling $45.1 million from the National Institute of Neurological Disorders and Stroke (“NINDS”)
The study will monitor safety, survival, clinical worsening, and key disease progression-related biomarkers while using CNM-Au8
Research conducted by Clene estimates that ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the US and an estimated 500,000 people worldwide, with a life expectancy of diagnosed patients typically ranging from three to five years
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company on a mission to transform the treatment of neurodegenerative diseases, recently announced that its wholly-owned subsidiary Clene Nanomedicine Inc., in collaboration with Columbia University and Synapticure, has been awarded a four-year grant totaling $45.1 million from the National Institute of Neurological Disorders and Stroke (“NINDS”). The grant will support an Expanded Access Protocol (“EAP”) for Clene’s investigational drug, CNM-Au8(R), for amyotrophic lateral sclerosis (“ALS”). The grant is supported by the National Institute of Health (“NIH”) grant U01NS136023 (https://ibn.fm/03fnZ).
An EAP, also called “Compassionate Use,” is an FDA-regulated pathway that allows people with serious and life-threatening diseases to access investigational drugs that have not yet been approved by the US Food and Drug Administration (“FDA”). In addition to the EAP, Clene plans to continue its current…
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Fr8Tech has witnessed a rise in carrier capacity, reporting a 60.8% year-over-year increase in August 2023 carrier capacity levels compared to August 2022
The average capacity levels through August rose 55.7% year-to-date
Luisa Lopez, Fr8Tech COO, attributed this growth to the company’s commitment to delivering quality services even during periods of downtime and securing high-quality carrier capacity
Fr8Tech also announced that Fr8App recently completed an integration with Geotab’s open API
The integration now allows Fr8App users to experience easy and precise tracking and monitoring of shipments
Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) is a North American transportation logistics technology company offering solutions that optimize logistics, reduce transportation costs, and improve experiences and efficiency for shippers and carriers in the U.S.-Mexico-Canada Agreement (“USMCA”) member countries.
The company has developed and is commercializing Fr8App, a custom-built freight-matching platform offering a real-time portal for B2B cross-border shipping and domestic shipping; Fr8Fleet, a digital platform that lets enterprise customers handle dedicated truck services, capacity, and…
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Scinai announced positive results suggesting the therapeutic potential of its anti-IL-17 VHH antibodies (NanoAbs) in treating plaque psoriasis
The preclinical study showed that the introduction of the NanoAbs downregulated the standard molecular markers S100A7, CXCL1, and CCL20, that are often overexpressed in plaque psoriasis
The study also revealed that the outer skin layers regained their normal appearance
The company aims to provide safe, efficacious, specific, and more convenient treatment for the large and underserved population of mild to moderate plaque psoriasis patients
Scinai is conducting an ex-vivo study to evaluate the anti-IL-17 NanoAbs in a full human skin model induced for psoriasis and intends to begin in-vivo animal studies early next year
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical and biotechnology company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological therapeutics, recently announced encouraging results from a preclinical study that suggest the therapeutic potential of the anti-interleukin 17 (“IL-17”) nanosized antibodies (“NanoAbs”) to relieve symptoms of plaque psoriasis (https://ibn.fm/mFsNO).
Plaque psoriasis is the most common psoriasis phenotype, affecting 80-90% of psoriatic patients (https://ibn.fm/oxKF7). It is caused by the excessive proliferation of keratinocytes (skin cells that, by secreting keratin, strengthen the skin, shield against UV penetration, and protect against…
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP) recently announced rapid enrollment in its potentially pivotal study involving its flagship drug candidate, Berubicin, and is moving closer to reporting the results of its drive toward a new treatment for the effectively incurable brain cancer glioblastoma (“GBM”). “The Texas-based company has clinical trial sites operating in the U.S., Italy, France, Spain, and Switzerland, to evaluate Berubicin’s performance against standard of care alkylating chemotherapy agent Lomustine for treating recurrent GBM. GBM has been generally untreatable by anthracyclines because of their inability to cross the blood-brain barrier, but Berubicin is believed to be able to cross the barrier and directly target central nervous system tumors. CNS Pharmaceuticals’ progress in enrolling patients for its potentially pivotal, global clinical trial indicates the company is on track to not only complete enrollment by the end of the year, but also to issue its planned futility interim analysis,” a recent article reads. “We are pleased to achieve this landmark milestone. Importantly, this takes us one step closer to bringing the study across the finish line and potentially offering an effective treatment in GBM that is safe and well tolerated,” CNS Pharmaceuticals CEO John Climaco is quoted as saying.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, is in the spotlight. Cepton cofounder and CEO Dr. Jun Pei is the featured guest on the latest release from Proactive. During the segment, Pei and Proactive host Steve Darling discussed the connection between LiDAR technology and eye safety, with Pei explaining how LIDAR can protect eyes. Pei also summarized how Cepton’s processes and approach ensures safety standards are met. During his comments, Pei observed that all devices placed on vehicles must meet regulatory eye safety standards and explained misconceptions about the impact of different wavelengths on safety; he also explained that eye safety is evaluated by several factors, including power, pulse rate, exposure time and wavelengths.
Pei noted that Cepton’s decision to use 905nm wavelengths for its LiDAR technology is not only for safety reasons but also because it offers other advantages, such as lower power consumption and reduced heat generation, which align with AI safety thresholds. “This interview with Dr. Jun Pei provides valuable insights into Cepton Inc.’s dedication to eye safety, the rationale behind using 905nm LiDAR technology, and the importance of transparently assuring customers of the safety and reliability of their products through third-party validation and data-backed evidence,” stated the press release.
Cepton is a Silicon Valley innovator of lidar-based solutions for automotive (“ADAS/AV”), smart cities, smart spaces and smart industrial applications. With its patented lidar technology, Cepton aims to take lidar mainstream and achieve a balanced approach to performance, cost and reliability, while enabling scalable and intelligent 3D-perception solutions across industries. Cepton has been awarded a significant ADAS lidar series production award with Koito on the General Motors Business. Cepton is also engaged with all top 10 global OEMs. Founded in 2016 and led by industry veterans with decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high-performance, high-quality lidar solutions. Cepton is headquartered in San Jose, California, and has a center of excellence facility in Troy, Michigan, to provide local support to automotive customers in the metro Detroit area. Cepton also has a presence in Germany, Canada, Japan, India and China to serve a fast-growing global customer base. For more information about this company, please visit www.Cepton.com.
NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is reporting on the status of the lawsuit it filed against TD Ameritrade, Charles Schwab, National Finance Services and others alleging that those broker dealers engaged in a scheme to manipulate the share price of the company’s securities. Mullen filed the lawsuit in August 2023 in the United States District Court in the Southern District of New York. The company is seeking compensatory damages and injunctive relief from the defendants “unlawful conduct in violation of Section 10b and Rule 10b-5 promulgated thereunder of the Securities Exchange Act of 1934.” Earlier this week, Judge Analisa Torres issued an order that Mullen should file an amended complaint by Nov. 30, 2023, and that the parties shall jointly file a case-management plan by Dec. 15, 2023.
According to the announcement, that plan requires certain dates be specified including the date defendants plan on filing any motion to dismiss as well as other key dates to be agreed to and/or ordered by the court. Mullen is aggressively pursuing all remedies available to protect the company and its shareholders. Representatives of the firms representing Mullen, including Christian Attar and Warshaw Burstein, are optimistic that wrongful conduct by the defendants will be exposed and they will be held responsible for all monies they have wrongfully extracted from Mullen and its shareholders. “This case raises certain unique legal issues concerning how broker-dealers manipulate the marketplace and how such manipulation impacts retail investors,” said Warshaw Burstein partner Alan M. Pollack in the press release. “Counsel will diligently work to expose defendants’ wrongdoing in order to protect the rights of Mullen and its shareholders.”
Mullen Automotive is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover; the Mullen I-GO Commercial Urban Delivery EV; the Mullen commercial class 1–3 EVs; and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and class 4–6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of all Electric Last Mile Solutions (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. To learn more about the company, visit www.MullenUSA.com.
NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN
About GreenCarStocks
GreenCarStocks (“GCS”) is a specialized communications platform with a focus on electric vehicles (“EVs”) and the green energy sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled recognition and brand awareness. GCS is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from GreenCarStocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the GreenCarStocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Combined company brings together two innovative platforms in AI and biotherapeutics to offer comprehensive solutions spanning early cancer detection, diagnostic insights, and targeted immunotherapies
The decision to join forces resulted from a carefully considered strategy to combine strengths and synergize work to elevate therapeutic efficacy and patient care
By joining forces, the two technology divisions will collaborate to push new boundaries in precision diagnostics and targeted treatments
GEDi Cube’s AI algorithms, trained using real-world data, could guide and accelerate Renovaro’s therapy development
Renovaro’s intimate knowledge about vital aspects of the immune system and how cancers could respond to treatment may help strengthen GEDi Cube’s AI technology
Renovaro BioSciences (NASDAQ: RENB), a preclinical biotechnology company involved in the development of enhanced gene, cell, and immunotherapy platforms that modulate immune responses against cancers and infectious diseases, and GEDi Cube International Ltd., an AI medical technology company, recently signed a definitive agreement to combine in a stock-for-stock acquisition (https://ibn.fm/gA9cq).
The combined company brings together renowned leaders across AI and immunotherapy, including Dr. Dybul, who brings decades of global health leadership experience; GEDi Cube CEO Craig Rhodes, the former head of Life Sciences for Europe, the Middle East, and North Africa at…
NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
LG’s South Korean mobile network operator LG U+ collaborated with KAIST (Korea Advanced Institute of Science and Technology) and Korea’s Qunova Computing to advance 6G satellite networks using the power of D-Wave’s quantum computing solutions
D-Wave’s annealing quantum computer has helped the companies successfully develop seamless connectivity of ground-to-satellite links and inter-satellite links
D-Wave is the world’s first commercial supplier of quantum computers and is helping customers apply practical quantum computing solutions to solve highly complex computational problems today
D-Wave Quantum (NYSE: QBTS) recently announced that LG U+, under the leadership of CEO Hyeon Sik Hwang, worked with the Korea Advanced Institute of Science and Technology (“KAIST”) and Qunova Computing to advance the development of a groundbreaking 6G low-earth orbit (“LEO”) satellite network. The network facilitates seamless connectivity of satellite-to-ground links (“SGLs”) and inter-satellite links (“ISLs”) that employ the power of D-Wave’s quantum computing system, successfully optimizing the intricate network.
The 6G LEO satellite network represents an innovative communication network that leverages ground stations and orbiting satellites within altitudes ranging from 500 to 10,000 km. SGLs and ISLs require a robust connection in order to achieve the highest level of…
NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
Forward-Looking Statements
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding whether advancing research in 6G and quantum communication will strengthen LG U+’s competitive edge. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the results of LG U+’s research in the relevant areas; general economic conditions and other risks; our ability to expand our customer base and the customer adoption of our solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of our business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of our products; the effects of competition on our business; the risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect our intellectual property; volatility in the price of our securities; the risk that our securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
SenesTech (NASDAQ: SNES), the rodent fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, presented virtually in a webcast presentation as part of of the Lytham Partners Fall 2023 Investor Conference. The company’s president and CEO Joel Fruendt and CFO Tom Chesterman joined Lytham Partners Managing Partner Robert Blum to provide an overview of the company and its unique positioning in the market. “At SenesTech, we have a significant opportunity to create something special. It’s why I joined the company in November of last year. We are addressing one of the world’s most challenging problems – rodent control – through a completely different way than has ever been done before by addressing the root cause of the problem – reproduction,” Fruendt said during the presentation. “The existing solutions’ effectiveness, namely poisons, that are in the marketplace are limited by rats’ reproduction rates, resistance and aversion as well well as the enhanced social and political limitations on the use of poison… As communities increasingly look to deploy sustainable, effective solutions, fertility control fits right in with that objective. Products that can be paradigm-changing don’t come along very often but, when they do, they have an opportunity to change the way things have been done for generations, and at SenesTech, we can do that.”
SenesTech is an expert in animal fertility control. The company’s passion is to create a healthy environment by better controlling animal pest populations. Keeping an inescapable truth in mind—that two rats and their descendants can be responsible for the birth of up to 15,000 pups after a year—SenesTech invented ContraPest(R), the only U.S. EPA registered contraceptive for male and female rats, and Evolve(TM) minimum risk soft bait. Its products fit seamlessly into all integrated pest management programs, greatly improving the overall goal of effective pest management. SenesTech strives for clean cities, efficient businesses and happy households – with a product designed to be effective and sustainable. The company is committed to improving the health of the world by humanely managing animal populations through fertility control. For more information about the company, visit www.SenesTech.com.
NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured at this month’s Virtual Investor Ask the CEO Conference. CNS Pharmaceuticals CEO John Climaco is scheduled to participate in a live moderated webcast during the conference; the webcast is slated to start at 4 p.m. ET. The distinctive conference provides a unique opportunity for members of the investment community to ask questions directly to leaders of specific companies during the live event. According to the announcement, executive answer as many questions as possible during the interactive webcast. A replay of Climaco’s “Ask the CEO” presentation will be available on the company website following the event.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anticancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information about the company, please visit www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, is planning to release its third-quarter 2023 financial results on Nov. 9, 2023; the report will be released following market close. Cepton has also scheduled a conference call and webcast for that same day; the call will begin 5:30 p.m. ET. During the call, management will discuss the quarter earnings report as well as provide a business update. The call can be accessed by dialing 1-877-300-8521 (toll free) or 1-412-317-6026 for international callers. According to the announcement, a replay of the conference call will be available approximately three hours after the live call through Nov. 23, 2023. The replay can be accessed by dialing 1-844-512-2921 (toll-free) or 1-412-317-6671 (international) and entering the passcode 10182348. An archived webcast of the conference call will be available on the company website.
Cepton is a Silicon Valley innovator of lidar-based solutions for automotive (“ADAS/AV”), smart cities, smart spaces and smart industrial applications. With its patented lidar technology, Cepton aims to take lidar mainstream and achieve a balanced approach to performance, cost and reliability, while enabling scalable and intelligent 3D-perception solutions across industries. Cepton has been awarded a significant ADAS lidar series production award with Koito on the General Motors Business. Cepton is also engaged with all top 10 global OEMs. Founded in 2016 and led by industry veterans with decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high-performance, high-quality lidar solutions. Cepton is headquartered in San Jose, California, and has a center of excellence facility in Troy, Michigan, to provide local support to automotive customers in the metro Detroit area. Cepton also has a presence in Germany, Canada, India and China to serve a fast-growing global customer base. For more information about this company, please visit www.Cepton.com.
NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN
About TinyGems
TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is hosting an upcoming virtual key opinion leader (“KOL”); the event will focus on the current state of lung cancer treatments and the challenges facing patients. Titled “Bringing Gene Therapy to the Fight Against Lung Cancer,” the event is slated for Oct. 27, 2023, at 12:30 p.m. ET. During the event, Alexander I. Spira, MD, PhD, FACP, and director of the Virginia Cancer Specialists (VCS) Research Institute and the phase I trial program at Johns Hopkins Hospital will join Daniel Morgensztern, MD, a professor of medicine and the director of thoracic oncology at Washington University School of Medicine; both doctors are medical oncologists.
The discussion will be facilitated by Genprex chief medical officer Mark S. Berger, MD. According to the announcement, the event, which will include a Q&A session with audience members, will spotlight Genprex’s lead product candidate REQORSA(R) (quaratusugene ozeplasmid) as a potential treatment for both non-small cell lung cancer (“NSCLC”) and small cell lung cancer (“SCLC”). Following the event, a replay of the event will be available on the Genprex website.
Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes that currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its proprietary, nonviral ONCOPREX(R)Nanoparticle Delivery System, which encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that are deficient in the tumor. The company’s lead product candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (“NSCLC”) and small cell lung cancer (“SCLC”). Each of Genprex’s three lung cancer clinical programs has received a fast-track designation from the Food and Drug Administration for the treatment of that patient population, and Genprex’s SCLC program has received an FDA Orphan Drug Designation. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an adeno-associated virus (“AAV”) vector to deliver Pdx1 (“Pdx1”) and MafA (“MafA”) genes to the pancreas. In models of type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-003 for type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. For more information, please visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
PaxMedica (NASDAQ: PXMD), a prominent clinical-stage biopharmaceutical firm, was featured in the latest episode of the Bell2Bell Podcast, a part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. PaxMedica’s CEO and Chairman Howard Weisman and Buzz Woods, from the company’s corporate communications department, joined the program to offer a compelling overview of the company’s recent achievements and future objectives. During the podcast, Weisman and Woods share insights into the company’s groundbreaking work in novel anti-purinergic drug therapies (“APT”) for neurologic conditions, primarily autism spectrum disorder (“ASD”). They discuss perspectives on PaxMedica’s initiatives and visionary advancements in the sphere of novel APT therapies, while sharing the company’s recent milestones and operational goals.
PaxMedica is a forward-looking clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (“APT”) designed to address challenging neurologic disorders. Its scope encompasses a spectrum of conditions, from neurodevelopmental disorders, including autism spectrum disorder (“ASD”), to the debilitating myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”), marked by both physical and cognitive burdens. PaxMedica prioritizes the advancement and evaluation of its flagship program, PAX-101—an intravenous suramin formulation—primarily focused on ASD treatment, while also broadening clinical insights into its potential applications for conditions such as ME/CFS. For more information, visit www.PaxMedica.com.
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software and services and the world’s first commercial supplier of quantum computers, has released a new open-source demonstration that highlights how the company’s Advantage(TM) annealing quantum computing system can be used to tackle wireless channel decoding. Available in the Leap(TM) real-time quantum cloud service from D-Wave, the demonstration is designed to identify solutions for increasing transmission capacity for wireless and cellular networks using coordinated multipoint decoding.
According to the announcement, nearly 12 billion mobile connections exist worldwide, and the wireless industry requires innovative solutions to ensure high-quality levels of service while reducing operational costs and power requirements. D-Wave’s quantum technologies are capable of solving a range of telecom-related challenges including employee scheduling for workforce resource management, network design and expansion planning, call center routing, and scheduling and routing of service vehicles, just to name a few.
“The commercialization of quantum is here, as a wide variety of companies spanning a diverse set of industries recognize the value that D-Wave’s technology can bring to driving operational excellence, today,” said D-Wave Quantum vice president of software, algorithms and cloud services Trevor Lanting in the press release. “In the world of wireless telecommunications, the high degree of complexity and large number of variables means a massive amount of computational power is required to solve challenging problems like increasing transmission capacity. Our demonstration shows how well our annealing quantum computing system can tackle challenges of this magnitude relative to classical computation, which could be transformative to network service providers.”
D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers — and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s customers include Volkswagen, Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California and Los Alamos National Laboratory. For more information about the company, please visit www.DWaveSys.com.
NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
Forward-Looking Statements
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential of D-Wave’s technology to address problems facing the telecom industry, and the potential impact on the telecom industry. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the ability of D-Wave’s technology to achieve similar results in a production environment; general economic conditions and other risks; our ability to expand our customer base and the customer adoption of our solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of our business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of our products; the effects of competition on our business; the risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect our intellectual property; volatility in the price of our securities; the risk that our securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Lucy Scientific Discovery (NASDAQ: LSDI), a pioneer in alternative mental-health treatments, is working to provide ingredients for effective mental-health treatment and therapies, including psilocybin and MDMA. According to a recent article spotlighting LSDI, the company is “well positioned” to support the mental-health space as it continues to grow. The article noted that mental-health issues are impacting millions of Americans a year and that treatments are finally evolving to treat these issues. Prescriptions for selective serotonin reuptake inhibitors (“SSRIs”) have long been a mainstay in the industry, but they don’t work for everyone and often have debilitating side effects. The article notes that wealthy investors are putting their money to work in alternative mind-medicine companies, bringing credibility to an industry that is ripe for innovation and growth. LSDI is gaining attention in that space as cannabis legalization across the country grows and clinical research into mental-health alternatives increases.
“Many of the states that have led the way in cannabis legalization are the same states pushing the legalization envelope for other alternative medicines, such as psilocybin and MDMA,” states the article. “The destigmatization of cannabis through legislative action set the precedent, encouraging research and investment into other psychoactive substances for medicinal use. . . . Accordingly, we witnessed completion of a second phase 3 study on MDMA, or ecstasy, which was successful at meeting the endpoints in treating PTSD. The MAPS study completion allows for the application submission for approval from the FDA, which is expected to be granted sometime in 2024. Lucy Scientific Discoveries is positioned to provide authorized support for many of these growing industries.”
Lucy Scientific Discovery is a NASDAQ company with holdings and operations in a variety of psychotropic businesses. The company holds a Controlled Drugs and Substances Dealer’s license granted by Health Canada’s Office of Controlled Substances. Lucy Scientific Discovery Inc. and its wholly owned subsidiary, LSDI Manufacturing Inc., operate under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada). This specialized license authorizes LSDI to develop, sell, deliver and manufacture pharmaceutical-grade active pharmaceutical ingredients (“APIs”) used in controlled substances and their raw material precursors. With a focus on pioneering innovative therapies for patients in need, Lucy Scientific Discovery is dedicated to advancing the understanding and applications of psychotropic medicines, improving mental health outcomes and enhancing well-being for individuals worldwide. For more information, visit the company’s website at www.LucyScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to LSDI are available in the company’s newsroom at https://ibn.fm/LSDI
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
SenesTech Inc. is building worldwide influence as a rat population control solution that humanely and cost-effectively based on fertility control
The company’s trademarked ContraPest(R) brand is designed to target rat pest populations large and small, as well as hard-to-get roof rodents, and is the only EPA-registered rat contraception product for both male and female rats
The rebound in rat populations worldwide in the wake of the COVID pandemic and a recent report on the spread of the rat lungworm parasite (which can sicken or kill humans) have fostered a new sense of concern about rat-carried diseases
SenesTech is expanding its international presence, with new client agreements this summer in The Maldives and South Africa. Additional discussions are underway in South America and Asia
Controlling rat populations and the diseases associated with them has been a concern for centuries, underlined in the public consciousness by historical plagues believed to be spread by rats, including the 14th century “Black Death” that remains the most fatal pandemic recorded in human history, causing the deaths of 75–200 million people (https://ibn.fm/DdhRa).
In the modern era, rat populations are rebounding in the wake of the COVID pandemic (https://ibn.fm/w8w6y) and in tandem with global climate change (https://ibn.fm/ldHpL), leading afflicted municipal authorities to seek creative solutions for coping with them. Some have proved…
NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, announced that it has innovated its investigational drug, CNM-Au8(R), with nanotechnology. Clene is evaluating CNM-Au8(R) for the treatment of neurodegenerative disease, and the innovation reflects the growing importance of nanotechnology in the drug space. The announcement noted that Clene’s nanotechnological approach was recently awarded a substantial grant by the National Institute of Neurological Disorders and Stroke (“NINDS”) of the National Institutes of Health (“NIH”) to conduct an Expanded Access Protocol in ALS.
The announcement also noted that Clene is planning to file a New Drug Application for CNM-Au8(R) for ALS indications in the first half of 2024. “October 2023 has turned into a month for the celebration of nanotechnology,” the announcement stated. “On Wednesday, Oct. 4, 2023, three U.S.-based scientists, Moungi Bawendi, Louis Brus and Aleksey Ekimov, were awarded the 2023 Nobel Prize in Chemistry for their discovery and synthesis of tiny clusters of atoms known as quantum dots, which are widely used today in applications as diverse as digital flat screens to surgery. On Friday, Oct. 6, the White House Office of Science and Technology Policy tweeted, ‘Happy #NationalNanoDay! #Nanotechnology is at the heart of many recent and emerging technologies, such as #NobelPrize winning #QuantumDots, higher energy density #batteries, hardware for #AI, and #QuantumComputers. What will nanotechnology enable in the future? Clene Nanomedicine believes that its lead asset, CNM-Au8(R), holds one such key to the future: the future of medicines to treat neurodegenerative disease.”
Clene is a biopharmaceutical company that aims to revolutionize the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s Disease and multiple sclerosis (“MS”). CNM-Au8 is manufactured by Clene using patented nanotechnology that results in an investigational drug with catalytic activity that targets mitochondrial health to improve neuronal function and survival. By increasing energy production and utilization inside cells, CNM-Au8 has been shown to enable neuroprotection and remyelination in multiple independent preclinical studies. For more information, please visit www.Clene.com.
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is seeing a striking response to its Strikingly Different road tour, which is designed to offer potential customers and other interested individuals an opportunity to directly interact with its vehicles. The tour’s next stop is scheduled on Oct. 23–24, 2023, at the Sonoma Motor Speedway. Those registering to attend the event will be contacted to reserve specific time slots, which allows them toe test drive specific Mullen vehicles. Mullen FIVE/GT/GTRS reservation holders have priority for booking time slots. “Join us on an exhilarating journey across the United States as we bring our groundbreaking electric vehicles to your doorstep,” the company states in the press release. “The second year of Mullen’s highly anticipated ‘Strikingly Different’ test drive tour offers you the unique opportunity to experience the future of transportation firsthand. Buckle up and feel the power of sustainable performance with the Mullen FIVE, Mullen FIVE RS and Mullen GT high-performance EVs or see how you can revolutionize your work style with our range of commercial EVs, including the Mullen ONE, Mullen THREE or Bollinger B2.”
Mullen Automotive is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover; the Mullen I-GO Commercial Urban Delivery EV; the Mullen commercial class 1–3 EVs; and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and class 4–6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of all Electric Last Mile Solutions (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. To learn more about the company, visit www.MullenUSA.com.
NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN
About GreenCarStocks
GreenCarStocks (“GCS”) is a specialized communications platform with a focus on electric vehicles (“EVs”) and the green energy sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled recognition and brand awareness. GCS is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from GreenCarStocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the GreenCarStocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
FingerMotion (NASDAQ: FNGR), a mobile services and data company, today released its financial results for the second quarter of fiscal 2024 for the period ended Aug. 31, 2023. Among the highlights, the company reported quarterly revenue of $9.28 million (includes SMS & MMS, telecommunications products and services businesses, and big data), reflecting an increase of $4.30 million or 86% compared to Q2 of fiscal 2023. “As our results show, the company is making excellent progress toward our goal of profitability,” said Martin Shen, CEO of FingerMotion. “It is easy to see our trajectory towards positive earnings results and how our proactive approach to fiscal management of our resources is materializing. One of the highlights of the quarter is the progress we are making towards break even.”
FingerMotion is an evolving technology company with a core competency in mobile payment and recharge platform solutions in China. As the user base of its primary business continues to grow, the company is developing additional value-added technologies to market to its users. The vision of the company is to rapidly grow the user base through organic means and have this growth develop into an ecosystem of users with high engagement rates utilizing its innovative applications. Developing a highly engaged ecosystem of users would strategically position the company to onboard larger customer bases. FingerMotion eventually hopes to serve over 1 billion users in the China market and eventually expand the model to other regional markets. For more information about the company, visit www.Fingermotion.com.
NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR
About ChineseWire
ChineseWire (“CW”) is a specialized communications platform with a focus on promising China-based companies that are listed in North America. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CW brings its clients unparalleled recognition and brand awareness. CW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the ChineseWire website applicable to all content provided by CW, wherever published or re-published: https://www.ChineseWire.com/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is spotlighted in a recent article focused on glioblastoma, the most aggressive type of brain cancer. Noting that glioblastoma has an average survival of only 14 to 16 months after diagnosis, the article points out that currently, glioblastoma has no cure and, because it is a highly invasive tumor, complete surgical removal is difficult. “Even with aggressive treatment, the cancer tends to recur, leading to a grim prognosis,” the article states. “The high mortality rate of glioblastoma is also due to its resistance to chemotherapy and radiation treatments, which can damage healthy brain tissue. Glioblastoma affects 12,000 to 15,000 people in the U.S. each year.” The article points out that one biopharmaceutical company working in the space is CNS Pharmaceuticals, which is focused on developing innovative therapies to treat diseases of the central nervous system (“CNS”). The article reports that CNS Pharmaceuticals’ lead product candidate is Berubicin, a chemotherapy drug being investigated for the treatment of glioblastoma that has received FDA Orphan Drug Designation.
“The innovation of Berubicin lies in its ability to overcome challenges specific to CNS tumor treatment,” the article states. “Traditionally, chemotherapy drugs struggle to reach the tumor cells in the brain due to the blood-brain barrier. Berubicin was specifically designed to solve this problem, and CNS Pharmaceuticals reports that it has demonstrated Berubicin’s ability to penetrate this barrier, enabling it to directly target cancer cells in the brain, an ability shared by very few chemotherapy drugs. This breakthrough feature enables the potential effectiveness of the treatment. . . . CNS Pharmaceuticals is actively conducting a potentially pivotal phase 2 clinical trial to evaluate the safety and effectiveness of Berubicin, with over 229 patients currently enrolled. This trial aims to assess the drug’s ability to improve outcomes for patients with glioblastoma.”
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anticancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information about the company, please visit www.CNSPharma.com
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
The BRAIN Foundation’s Synchrony Symposia is the first and only international symposium on translational research for Autism Spectrum Disorder (“ASD”)
PaxMedica Chairman and CEO Howard Weisman says that participating at the symposium is pivotal in advancing and fostering autism research
As a Gold Sponsor, PaxMedica will have purview to the symposium’s interdisciplinary discussions, insights, and research presentations, clinical roundtables, mentor-mentee sessions, and more
PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of Autism Spectrum Disorder (“ASD”) and other serious conditions with intractable neurologic symptoms, recently announced its Gold Sponsorship of The BRAIN Foundation’s esteemed Synchrony Symposia 2023. The BRAIN Foundation supports translational research that will lead to the development of FDA-approved treatments and an improved standard of care for co-morbidities in individuals with ASD.
The Synchrony Symposia is the first and only international symposium on translational research for ASD – bringing together academia, biotech, pharmaceutical companies, venture partners, and more to catalyze scientific research that can improve health and the quality of life for people with autism and other…
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has released a commercial vehicle production update for its Class 3 EV cab chassis trucks and Class 1 EV cargo vans. According to the report, the company is on track to produce 150 Class 3 EV trucks through December 2023 and to begin production and delivery of its Class 1 EV cargo van in Q4 2023. Specifically, the report noted that the company’s Class 3 production plans for the remainder of 2023 include an estimated 150 vehicles to be produced and delivered to Randy Marion Automotive Group (“RMA”), noting that the first 10 Class 3 vehicles were delivered to RMA last month. In addition, Mullen expects to deliver the balance of the 1,000 Class 3 vehicle purchase order in calendar year 2024. Mullen’s Class 1 EV cargo van production is on track to begin in Q4 2023, with the production of an estimated 300 vehicles initially planned and increasing numbers projected when the facility is in full production.
In summary, the report noted that total planned commercial vehicle production for calendar years 2023 and 2024 includes 150 Class 3 EV cab chassis trucks and 300 Class 1 EV cargo vans in 2023, with 850 Class 3 EV cab chassis trucks and 6,000 Class 1 EV cargo vans planned for 2024. “I am proud to say both our Class 3 production acceleration and our Class 1 manufacturing preparations are on track at our Tunica assembly plant,” said Mullen Automotive CEO and chair David Michery in the press release. “We have firmed up our production schedules for 2024, which align with our existing customer orders and provide ample room for additional customer demand.”
Mullen Automotive is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover; the Mullen I-GO Commercial Urban Delivery EV; the Mullen commercial class 1–3 EVs; and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and class 4–6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of all Electric Last Mile Solutions (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. To learn more about the company, visit www.MullenUSA.com.
NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN
About GreenCarStocks
GreenCarStocks (“GCS”) is a specialized communications platform with a focus on electric vehicles (“EVs”) and the green energy sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled recognition and brand awareness. GCS is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from GreenCarStocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the GreenCarStocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, has announced that its crime-fighting tech portfolio is expanding with the addition of the K1 Hemisphere. According to the announcement, the K1 is the company’s smallest machine to date. The new ASR carries the slogan: Half a World of Information at Your Fingertips.
The announcement noted that the Hemisphere has undergone a rigorous product development cycle that included real-world testing by a client in Hawaii. After the evaluation period, Knightscope finalized production details and approved a full product release. According to the company, it has received numerous preorders from a variety of clients; those orders will begin to be filled now.
Designed to be mounted to an array of surfaces or objects, the new device features three cameras that provide up to 210 degrees of eye-level, high-definition video as well as a strobe light, automatic license plate recognition, automated broadcast announcements and intercom capability that can be run on a wired or fully encrypted wireless network. An optional facial recognition feature is also available. In addition, two Hemispheres can be placed back-to-back to provide a complete 360-degree view of any given area.
“The K1 Hemisphere is a perfect entry point into deploying Knightscope’s advanced technologies to help protect the places people live, work, study and visit,” stated the company in the announcement. “The Hemisphere is ideally suited for ATM vestibules, hallways, HOAs, loading docks, lobbies/reception areas, ports, rail yards/platforms, reception areas, schools, stairwells, truck stops and any other places where the security and safety profile may be elevated.”
Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information about the company, please visit www.Knightscope.com.
NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, closed on its previously announced registered direct offering. The offering was comprised of 2,424,243 shares of Class A common stock or common stock equivalents priced at $1.65 per share, or common stock equivalent. In addition, Longeveron issued unregistered Series A warrants in a concurrent private placement; the private placement included 2,424,243 shares of LGVN common stock and unregistered Series B warrants. The warrants, which have an exercise price of $1.65 per share, are exercisable upon the effective date of stockholder approval of the issuance of the shares underlying the warrants. The Series A and Series B warrants have terms of five and one-half years and 18 months from the date of issuance, respectively. According to the announcement, Longeveron anticipates using the estimated $4 million gross proceeds from the offering for ongoing clinical and regulatory development of Lomecel-B(TM) as well as for capital expenditures, working capital and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Longeveron is a clinical-stage, biotechnology company developing regenerative medicines to address unmet medical needs. The company’s lead investigational product is Lomecel-B(TM), an allogeneic medicinal signaling cell (“MSC”) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action encompassing provascular, proregenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently advancing Lomecel-B through clinical trials in three indications: hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty. To learn more about the company, visit www.Longeveron.com.
NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at https://ibn.fm/LGVN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Lexaria recently announced its intention to launch new human and animal studies exploring its patented DehydraTECH(TM) technology on GLP-1 drugs for the potential treatment of diabetes
The studies will build on what Lexaria has achieved so far since it started its diabetes-related studies in 2022
Its DehydraTECH-CBD demonstrated an almost three-fold improvement in drug delivery into the blood in its DIAB-A22-1 diabetes study compared to the DehydraTECH-CBD formulation used in its HYPER-H21-4 hypertension study
These studies follow Lexaria’s announcement of its intention to study weight loss and diabetes control in a human population using DehydraTECH
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its intention to launch new human and animal studies that will explore its patented DehydraTECH(TM) technology on glucagon-like peptide-1 (“GLP-1”) drugs for improved bioavailability, cost-effectiveness, tolerability, weight loss potential, management of diabetes and other health conditions. Regarded as a significant expansion for Lexaria, these studies will build on what the company has achieved so far with its DehydraTECH-processed CBD while examining the technology’s impact on GLP-1 drugs (https://cnw.fm/Np3FA).
The U.S. Food and Drug Administration (“FDA”) recently approved GLP-1 drugs for type 2 diabetes and weight loss management following their demonstration of an average loss of 15% of body weight across 667 individuals in a 68-week-long study. The drug has also demonstrated that some patients experience…
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CBDWire
CBDWire (“CBDW”) is a specialized communications platform with a focus on CBD related news and updates in the cannabidiol (“CBD”) sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled recognition and brand awareness.
CBDW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CBDWire, text “CBDWire” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer
SenesTech pioneered an innovative rat control method that restricts the fertility of both male and female rats, ContraPest(R)
With cities around the country and the world, in general, implementing a raft of rat control methods, SenesTech is eager to work with city governments to address the rat crises
Rat populations are surging in many major cities, driven by the post-COVID rebound in business and climate change
Studies show that ContraPest can reduce rat populations by more than 90% and sustain the reduced numbers, when added to an integrated pest management plan
Once threatened by the sudden COVID-induced closure of businesses and restaurants, which forced rats to adapt by moving to residential areas in search of food or die – renowned rodentologist Bobby Corrigan estimates that hundreds of thousands, if not millions, died – the long-tailed rodents are now seemingly enjoying a change of fortune. Rat populations are surging in many major cities, driven by the post-COVID rebound in restaurant operations and the reopening of businesses, which are providing alternative and ample locations where the rodents find food. Moreover, “Climate change has brought longer stretches of warmer weather, which means more time for breeding,” explains an article in PBS (https://ibn.fm/Pqceu).
This is concerning. Rats cause billions of dollars in damages annually worldwide and carry harmful and sometimes deadly diseases. Thus, to avert a crisis, cities have moved to control the vermin, turning their attention toward addressing the trash problem as one of their…
NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
In line with recent emphasis on the growing importance of nanotechnology in the US, Clene Nanomedicine innovated its investigational drug, CNM-Au8(R), using nanotechnology for the treatment of neurodegenerative disease
Clene’s nanotechnological approach was recently recognized by the NINDS of NIH with a substantial grant to conduct an Expanded Access Protocol in ALS with CNM-Au8(R)
Clene aims to file a New Drug Application for CNM-Au8(R) for ALS indications in the first half of 2024
October 2023 has turned into a month for the celebration of nanotechnology. On Wednesday, Oct. 4, 2023, three U.S.-based scientists, Moungi Bawendi, Louis Brus, and Aleksey Ekimov, were awarded the 2023 Nobel Prize in Chemistry for their discovery and synthesis of tiny clusters of atoms known as quantum dots, which are widely used today in applications as diverse as digital flat screens to surgery. On Friday, Oct. 6, the White House Office of Science and Technology Policy tweeted, “Happy #NationalNanoDay! #Nanotechnology is at the heart of many recent and emerging technologies, such as #NobelPrize winning #QuantumDots, higher energy density #batteries, hardware for #AI, and #QuantumComputers. What will nanotechnology enable in the future?” Clene Nanomedicine believes that its lead asset, CNM-Au8(R), holds one such key to the future: the future of medicines to treat neurodegenerative disease.
Clene (NASDAQ: CLNN) is a biopharmaceutical company that aims to revolutionize the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s Disease, and multiple sclerosis (“MS”). CNM-Au8 is manufactured by Clene using patented nanotechnology that…
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, today announced that, through a new e-commerce distribution agreement, it will enable the online sales of OPKO Health Europe, a subsidiary of OPKO Health (NASDAQ: OPK) products in China. Under the agreement terms, NextPlat will launch a OPKO Health-branded online storefront on Alibaba Group Holding Limited’s (NYSE: BABA) Tmall Global e-commerce platform in China featuring an assortment of nutraceutical and veterinary products sold and distributed by OPKO Europe. “NextPlat’s focus is to enable companies across an array of high-growth sectors, such as health care and consumer products, to capitalize on the vast opportunities of global e-commerce. Having already successfully built a sizable portfolio of products for human and animal health, we believe OPKO Europe is an ideal customer for our new e-commerce development program,” said Charles M. Fernandez, executive chairman and CEO of NextPlat. “By leveraging our online expertise, capabilities and our expanded relationship with Alibaba, we can uniquely provide OPKO Europe with a reliable and efficient way to quickly begin selling its products online to potentially millions of new consumers in China.”
NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company intends to assist businesses in selling their goods online, domestically and internationally, allowing customers and partners to optimize their e-commerce presence and revenue. NextPlat currently operates an e-commerce communications division offering voice, data, tracking, and IoT products and services worldwide and pharmacy and healthcare data management services in the United States.
NOTE TO INVESTORS: The latest news and updates relating to NXPL are available in the company’s newsroom at https://ibn.fm/NXPL
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, announced two new sales for its K5 ASRs and an expansion sale from an existing user of its K1B line of emergency communication systems.
The announcement reads, “Two Portland, Oregon, hotels each signed contracts for Knightscope ASRs to patrol their parking areas after the word-of-mouth-success of another Portland area hotel. Security in hospitality encompasses a hotel’s building and grounds as well as its guests, employees, visitors and day users. As recently outlined in Knightscope’s Blog, operators and administrators must follow an integrated approach when adding ASRs, observing all aspects of security to ensure the optimal combination of organizational, technical and physical measures to prevent and respond in a timely manner to any dangerous situation. Knightscope ASRs patrolling the perimeter will alert personnel to certain threats, allowing them to respond quickly when assistance is needed.
“Following a previously announced sale of 22 devices, a Florida college is expanding its emergency communications program and retrofitting a competitor’s products with Knightscope’s K1 Retrofit Kits and faceplates. In order to prevent school shootings and other types of crime from occurring in our educational institutions, it is crucial to invest in a wide array of approaches that systematically create safe, healthy and supportive schools for all students rather than just hardening access to them. Knightscope’s blue light phones and towers provide reliable communications throughout school campuses to access emergency assistance.”
Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information, visit the company’s website at www.knightscope.com.
NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has been granted two new patents by the Canadian Intellectual Property Office (“CIPO”), increasing its portfolio to 37 granted patents. According to the update, Canadian Patent #2,984,917, “ Stable Ready-to-drink Beverage Compositions Comprising Lipophilic Active Agents, ” was granted on Sept. 26, 2023, and expires Dec. 1, 2036. The patent recognizes Lexaria’s innovations in delivering lipophilic (fat-based) active drugs and active molecules suspended in a water-based format. Lexaria’s DehydraTECH technology can be used in dry formats such as capsules and pills, as well as in liquid formats such as drops, tinctures and also beverages including consumer beverages. This is the company’s sixth granted patent in its patent family.
Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 37 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has entered into a definitive agreement for the issuance and sale shares of its common stock. Specifically, the agreement calls for the issue and sale of 2,424,243 shares of Class A common stock, or common stock equivalents, for $1.65 per share in a registered direct offering. The announcement also noted that a concurrent private placement calling for Longeveron to issue and sell unregistered Series A warrants to purchase up to 2,424,243 shares of its common stock and unregistered Series B warrants to purchase up to 2,424,243 shares. The company anticipates the offering will close on or about Oct. 13, 2023, and will be subject to customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Longeveron is a clinical-stage, biotechnology company developing regenerative medicines to address unmet medical needs. The company’s lead investigational product is Lomecel-B(TM), an allogeneic medicinal signaling cell (“MSC”) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action encompassing provascular, proregenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently advancing Lomecel-B through clinical trials in three indications: hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty. To learn more about the company, visit www.Longeveron.com.
NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at https://ibn.fm/LGVN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Howard Weisman presented PaxMedica’s goals and plans to investors at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023
The presentation defined the company’s intention to generate significant funding for its ASD program by first gaining approval for suramin sodium in the treatment of a rare and deadly infection using the same drug
The global ASD treatment market was valued at $2.02 billion and is expected to reach $3.28 billion by 2030
Howard Weisman, CEO of PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”) for the treatment of Autism Spectrum Disorder (“ASD”) and other serious conditions with intractable neurological symptoms, recently participated in the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023. He presented the company’s presentation to investors, expressing the company’s overall goals and plans for its lead programs – PAX-101 and PAX-102. He also participated in one-on-one meetings with investors registered at the conference.
As expressed by Mr. Weisman in the company’s presentation, PaxMedica plans to develop a drug for autism using suramin sodium, which was created in the past to treat Human African Trypanosomiasis (“HAT”), a deadly form of sleeping sickness, but was discontinued. PaxMedica plans to use data from…
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
SuperCom recently secured a new national program to deploy its Domestic Violence Monitoring Solution to the government of Finland
Last year, Finland’s Parliament adopted the Finnish government’s proposal to enhance the effectiveness of the country’s law on restraining orders, resulting in a strengthened law that allows the court to order electronic monitoring of offenders
SuperCom will deploy several innovative and proven technologies that are part of its PureSecurity EM Suite, including the PureProtect mobile phone application, PureTrack smartphone, PureTag ankle bracelet, and PureMonitor cloud-based monitoring software
The new program follows a successful project with the Finnish government that saw SuperCom deploy its PureSecurity EM Suite to reduce prison overcrowding and lower recidivism
SuperCom (NASDAQ: SPCB), a leading provider of advanced safety, identification, and security products and solutions to governments as well as public and private organizations globally, recently announced it had secured a new national program to deploy its Domestic Violence Monitoring Solution to the government of Finland. The project aims to safeguard victims, proactively prevent domestic violence, and empower Finnish authorities with advanced technologies that enhance the safety and well-being of the country’s citizenry (https://ibn.fm/8i8Z1).
A part of SuperCom’s family of PureSecurity Electronic Monitoring (“EM”) products, the Domestic Violence Monitoring Solution includes several innovative and proven technologies: PureProtect mobile phone application, PureTrack smartphone, PureTag ankle bracelet, and PureMonitor cloud-based monitoring…
NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software and services and the world’s first commercial supplier of quantum computers, is working with Satispay, the leading Italian fintech unicorn revolutionizing mobile payments. The two companies have built a quantum-hybrid application designed to optimize customer rewards initiatives. According to the announcement, the quantum-optimized rewards application shows 50% improvement in customer rewards programs for the same amount of budget.
The announcement noted that Satispay has plans to transition the quantum-hybrid application into production. Satispay is seeing increased adoption of its services in countries such as Italy and France as users look for a seamless, secure and easy way to send, receive and spend money.
“Digital payments represent one of the fastest-growing trends in financial services,” D-Wave Quantum vice president of quantum business innovation Murray Thom in the press release. “By applying the power of quantum-hybrid technology to optimize Satispay’s customer acquisition strategies, we’re helping one of Europe’s top fintech companies unlock a competitive advantage and bring its independent payment network to more customers, faster.”
D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers — and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s customers include Volkswagen, Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California and Los Alamos National Laboratory. For more information about the company, please visit www.DWaveSys.com.
NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
Forward-Looking Statements
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding Satispay’s plans to transition the application to production and the potential impact of the application once in production. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the timing of Satispay’s transition of the application into production and the continued positive impact of the application once in production; general economic conditions and other risks; our ability to expand our customer base and the customer adoption of our solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of our business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of our products; the effects of competition on our business; the risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect our intellectual property; volatility in the price of our securities; the risk that our securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.
About AINewsWire
AINewsWire (“AINW”) is a specialized communications platform with a focus on the latest advancements in artificial intelligence (“AI”), including the technologies, trends and trailblazers driving innovation forward. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, AINW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, AINW brings its clients unparalleled recognition and brand awareness.
AINW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from AINewsWire, text “AI” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the AINewsWire website applicable to all content provided by AINW, wherever published or re-published: https://www.AINewsWire.com/Disclaimer
Renovaro BioSciences (NASDAQ: RENB), a biotechnology corporation focusing on cell, gene and immunotherapy, has announced a new member of its board of directors. Avram Miller, cofounder of Intel Capital, will join the board and will also serve in an advisory role, bringing his invaluable experience to contribute to the company’s strategy and business development efforts. Miller’s impressive decades-long career includes strategic and responsible roles in both the technology and medical industries. After spending 13 years in the medical science space, he moved to high tech where, in addition to cofounding Intel Capital, he served as the company’s corporate vice president of business development. In the last decade, he has found a way to combine technology with health care, including serving in an advisory role to prominent institutions such as the Cleveland Clinic and Sheba Medical Center and coaching as well as investing in many early-stage med-tech startups.
“Avram’s unique background in medical science and technology and, in particular, his experience dealing with the opportunities fueled by rapid technological changes will help guide our business,” said Renovaro Biosciences board chair Rene Sindlev in the press release. “We believe his vast business experience working with companies at all stages of development will be instrumental as we move into the commercial phase of our business.”
Renovaro BioSciences has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases. For more information about the company, visit www.RenovaroBio.com.
NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting enrollment of 229 participants in its ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer; the company expects to ultimately enroll 243 in the study. Participants are being enrolled in 46 clinical trial sites across the United States, Italy, France, Spain and Switzerland. According to the announcement, CNS Pharmaceuticals is on track to achieve value-driving milestones before the end of the year, including reporting topline results of interim analysis expected and completing enrollment in Q4 2023.
“The momentum in patient enrollment for this important study has frankly exceeded even our own high expectations,” said CNS Pharmaceuticals CEO John Climaco in the press release. “Recall that each patient who joins our study does so after their disease has recurred following the failure of standard of care treatment, an excruciating and deeply challenging moment in their life and their battle against glioblastoma. The confidence and trust these patients and their physician teams are demonstrating in our work is truly gratifying. With the sustained rapid pace of enrollment we’ve experienced here and in Europe, we are clearly on track to achieve complete enrollment of our study before year end. Perhaps even more importantly, we also expect to report results from the interim analysis later this quarter, with data derived from the robust sample set we have desired from the beginning as we seek to conclusively demonstrate Berubicin’s potential. As we continue to drive this study forward, we remain hopeful in our effort to address this devastating disease and potentially offering an effective treatment in GBM that is safe and well tolerated.”
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anticancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. For more information about the company, please visit www.CNSPharma.com
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
PaxMedica (NASDAQ: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions, today announced its Gold Sponsorship of The BRAIN Foundation’s esteemed Synchrony Symposia 2023. The globally recognized event serves as a catalyst for translational research in autism and related neurodevelopmental disorders and brings together leading scientists, clinicians, biotech and pharmaceutical companies, venture partners, and community stakeholders to foster scientific advancements that can enhance the well-being and quality of life for individuals affected by ASD. “We are honored to support The BRAIN Foundation’s Synchrony Symposia. This symposium plays a pivotal role in advancing scientific knowledge and fostering collaboration among experts in the field of autism research,” said Howard Weisman, chairman and CEO of PaxMedica. “PaxMedica is deeply committed to improving the lives of individuals with autism and their families, and we are excited to contribute to this vital initiative.”
PaxMedica is a clinical stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (“ASD”) to myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”), a debilitating physical and cognitive disorder. One of PaxMedica’s primary points of focus is the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and the advancing the clinical understanding of using that agent against other disorders such as ME/CFS. For more information, visit www.PaxMedica.com.
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Renovaro BioSciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, today announced the appointment of Leni Boeren and Ruud Hendriks as independent directors. Both Boeren and Hendriks bring extensive, high-level experience in finance and business. Boeren has a 40-year career in the financial sector, commencing with banking roles at Paribas and Rabobank before holding several director-level positions at Amsterdam exchanges and then Euronext. Hendriks brings more than 35 years of experience in the asset management industry, having held senior roles at some of the most established financial institutions. “On behalf of the board, I am delighted to welcome Leni and Ruud as our newest independent directors at this pivotal moment for our business,” said Rene Sindlev, chairman of Renovaro. “Their substantial experience in the capital markets and asset management will bring invaluable financial and business expertise as we advance towards commercialization.
Renovaro has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases. For more information on Renovaro, visit the company’s website at www.Renovarobio.com.
NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, is featured in the latest Bell2Bell Podcast release. During the segment, podcast host Stuart Smith discusses the company with Clene president and CEO Rob Etherington, who explains Clene’s business model and provides an overview of recent developments, which provide hope to those affected by neurodegenerative conditions. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. “Clene spends every waking moment working on amyotrophic lateral sclerosis (‘ALS’), a devastating neurodegenerative condition,” said Clene president and CEO Rob Etherington during the interview.
“We are focused on neurodegenerative diseases generally – including multiple sclerosis and Parkinson’s – but our body of evidence that has really come to the forefront in the last few years has been all around ALS. . . . The timing is important because this remains a remarkably devastating disease with life mortality of three to five years from diagnosis. It remains uniformly and universally fatal. . . . .It’s just devastating and tragic. Gratefully, the U.S. FDA has approved, in the last year, two new drugs: one for a very rare form of the disease that is a genetic, inborn error that runs in a devastating way through families, and, for general ALS, another drug was approved last November. Thankfully, there are many drugs in development presently, including our own drug, CNM-Au8(R).”
Clene and its wholly owned subsidiary, Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
SenesTech (NASDAQ: SNES), animal pest fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, will be participating in this month’s Lytham Partners Fall 2023 Investor Conference; the conference is slated for Oct. 17, 2023. According to the announcement, SenesTech CEO Joel Fruendt and CFO Tom Chesterman will present during the elite event. Their presentation is scheduled to begin at 7 a.m. ET. In addition, the two company officials will be available to host one-on-one meetings with investors.
SenesTech is committed to being “the pest-control difference” for the 21st century. The company’s passion is to create a healthy environment by virtually eliminating rodent pest populations. The company keeps an inescapable truth in mind: two rats and their descendants can be responsible for the birth of up to 15,000 pups after a year. SenesTech invented ContraPest, the only U.S. EPA-registered contraceptive for male and female rats. ContraPest fits seamlessly into all integrated pest-management programs, greatly improving the overall goal of effective rat management. The company strives for clean cities, efficient businesses and happy households — with a product that was designed to be effective and sustainable without killing rats. For more information about the company, please visit www.SenesTech.com.
NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots and blue light emergency communication systems, is seeing consistent success and growth as the company has announced a string of new orders. Most recently, the company has signed three new contracts for five devices to be used by clients in New York, Nevada, and Oklahoma.
The new orders represent the value and diversity Knightscope products for an array of uses and across a broad spectrum. The Knightscope devices will be used on a college campus in New York, a park in Oklahoma and a city in Nevada.
“The goal of a strong emergency communications system is to provide a platform for individuals to reduce the number of possibilities for criminals to commit a crime,” Knightscope stated in the press release. “A University of Southern California study found that public venues with visible security equipment like blue light emergency towers and phones increased the area’s perceived safety, making people feel more comfortable at such locations/venues. The objective is straightforward: when someone identifies their own personal vulnerability to crime, they can mitigate the risk by taking preventative measures and communicating with authorities. These three new users are taking proactive measures to build a robust and reliable communications pipeline for employees, faculty, students and visitors to reach professional help when in need or in the case of a life-threatening emergency.”
Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information about the company, please visit www.Knightscope.com.
NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
FRGT, through its growing suite of solutions, is proving to be a formidable B2B cross-border shipping player in the NAFTA region
Its ambitious efforts have seen the company join AMACARGA while also integrating with Samsara and collaborating with Trucker Tools
By doing so, FRGT is helping the freight transportation marketplace to move commerce efficiently
Freight Technologies (NASDAQ: FRGT), a tech company on a mission to revolutionize cross-border shipping by offering carriers increased growth opportunities and shippers with flexibility, visibility, and simplicity, remains committed to helping the freight transportation marketplace to move commerce efficiently. Its recent push for its load-matching solution Fr8App, coupled with notable moves such as its collaboration with Trucker Tools, an automated booking solutions platform, reflects this commitment while pointing to the company’s current direction and plans.
Just recently, a new bill, Assembly AB 316, was tabled in California, proposing that heavy-duty autonomous trucks ought to be manned until such a point where tests conclusively show that these trucks would not be a threat. There has been a push for crewless autonomous trucks, with those…
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced the appointment of Marianne McInerney as chief strategy officer. According to the announcement, McInerney will focus on growth opportunities and drive strategic initiatives for Mullen’s commercial, consumer vehicles and governmental affairs. McInerney has nearly two decades of experience in the automotive and transportation industry, during which she has advised multiple original equipment manufacturers, governmental entities and tier one suppliers and held vital positions at next-generation vehicle OEMs, the U.S. Department of Transportation, and the American International Automobile Dealers Association. “Marianne is a key addition to our team and her leadership and experience will set a growth strategy to expand and drive strong top and bottom-line impacts for Mullen at the commercial, consumer and governmental levels,” said David Michery, CEO and chairman of Mullen Automotive. “She brings a vast level of domestic and international OEM experience and will deliver innovative strategies to strengthen our market share globally.”
Mullen is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen-GO Commercial Urban Delivery EV, Mullen Commercial Class 1-3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. For more information about the company, visit www.MullenUSA.com.
NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN
About GreenCarStocks
GreenCarStocks (“GCS”) is a specialized communications platform with a focus on electric vehicles (“EVs”) and the green energy sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled recognition and brand awareness. GCS is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from GreenCarStocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the GreenCarStocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Longeveron (NASDAQ: LGVN; LGVNR), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has released top-line results for its phase 2a trial of its investigational product Lomecel-B(TM). The study evaluated Lomecel-B for the treatment of mild Alzheimer’s disease. According to the report, the primary endpoint of safety was met across all study groups; in addition, the secondary endpoint of change from baseline to week 39 in Composite Alzheimer’s Disease Score (“CADS”) also demonstrated positive results. The report also noted that other doses demonstrated numerical slowing/prevention of disease worsening relative to placebo.
“We believe these results provide important validation of both the safety and therapeutic potential of Lomecel-B in the treatment of Alzheimer’s disease and provide a robust foundation for additional clinical trials in this and other indications,” said Longeveron CEO Wa’el Hashad in the press release. “We look forward to announcing additional biomarker data from this trial, anticipated to be later this month, which may further characterize the clinical effects of Lomecel-B in this study population. With our phase 2 ELPIS II trial in HLHS moving toward anticipated completion in 2024, and our phase 2 program in Aging-Related Frailty progressing in Japan as well, we look forward to meaningful milestones in the near term and to fully realizing the therapeutic potential of Lomecel-B.”
Longeveron is a clinical-stage, biotechnology company developing regenerative medicines to address unmet medical needs. The company’s lead investigational product is Lomecel-B(TM), an allogeneic medicinal signaling cell (“MSC”) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action encompassing provascular, proregenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently advancing Lomecel-B through clinical trials in three indications: hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty. To learn more about the company, visit www.Longeveron.com.
NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at https://ibn.fm/LGVN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Clene (NASDAQ: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc. in collaboration with Columbia University and Synapticure, was awarded a four-year grant totaling $45.1 million from the National Institute of Neurological Disorders and Stroke (“NINDS”), a division of the National Institutes of Health (“NIH”). The grant is to support an Expanded Access Protocol (“EAP”) for the company’s investigational drug, CNM-Au8(R), in amyotrophic lateral sclerosis (“ALS”). Also referred to as Compassionate Use, an EAP is an FDA-regulated pathway that allows people with a serious and life-threatening disease to access an investigational drug that is not yet approved by the U.S. Food and Drug Administration (“FDA”). “This EAP study will give ALS patients who don’t meet the criteria to enroll in a clinical trial an opportunity to try CNM-Au8 as a novel investigational therapy through this EAP program,” said Jinsy A. Andrews, M.D., MSc, FAAN, an associate professor of neurology in the Division of Neuromuscular Medicine and director of Neuromuscular Clinical Trials at Columbia University Vagelos College of Physicians and Surgeons. “Programs like this help to advance research and much-needed innovation in ALS.”
Clene, along with its subsidiaries and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s and multiple sclerosis. CNM-Au8(R) is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information about the company, visit www.Clene.com.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
The fluxonium qubits that D-Wave has designed, manufactured, and operated demonstrate properties comparable to the best in scientific literature to date
D-Wave has manufactured and tested fluxonium qubits in a two-dimensional circuit geometry, measuring several factors
D-Wave owns one of the industry’s largest quantum computer intellectual property portfolios, with more than 210 issued U.S. patents, and has published more than 100 peer-reviewed papers in leading scientific journals
D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the world’s first commercial supplier of quantum computers, recently announced notable progress in its development of high-coherence qubits, with results expected to have a significant impact on its future quantum technologies. The fluxonium qubits that D-Wave has designed, manufactured, and operated demonstrate quantum properties comparable to the best in scientific literature to date.
The fluxonium qubit was pioneered by Michel Devoret and his colleagues at Yale University in 2009 and has recently become an attractive candidate for use in next-generation gate model quantum computing architectures. With the industry’s growing interest and D-Wave’s expertise in flux-like quantum…
NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
Forward-Looking Statements
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding expectations of how the results of D-Wave’s progress with fluxonium qubits may impact its future quantum technologies and hardware development, including its gate model program; the conclusion that fluxonium may be a viable candidate qubit for D-Wave’s gate model quantum computing architectures; the broad applicability that quantum computing is expected to have to computationally complex problems across industries; the probability that enterprises will invest in quantum computing and the expected amount of such investments; and the ability of quantum computing to help businesses achieve value and to surpass their competition. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the results of further development of fluxonium qubits by D-Wave; the development by other companies of fluxonium qubits that may surpass D-Wave’s technology; the viability of fluxonium qubits as candidates for D-Wave’s gate model quantum computing architectures; the success of fluxonium qubits in gate model quantum computing architectures, if chosen for such purposes; whether fluxonium continues to address some of the known shortcomings of competing superconducting gate model qubits; general economic conditions and other risks; the company’s ability to expand its customer base and the customer adoption of its solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of the company’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of the company’s products; the effects of competition on the company’s business; the risk that D-Wave will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that D-Wave may never achieve or sustain profitability; the risk that the company is unable to secure or protect its intellectual property; volatility in the price of the company’s securities; the risk that the company’s securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. The company undertakes no duty to update this information unless required by law.
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots and blue light emergency communication systems, has announced two new contracts from a Los Angeles area shopping center and a medical clinic.
The announcement reads, “The Knightscope K5 Autonomous Security Robot (‘ASR’) will be patrolling the interior of a large, cultural mall in the Los Angeles area. Shopping centers are places where people go to shop, dine, relax, browse or meet in a fun and safe atmosphere. Providing that safe environment reduces vacancies, mitigates risk, elevates property values and increases foot traffic. Knightscope ASRs have already successfully deterred substance abuse, vehicle break-ins, trespassing/loitering, vandalism, theft and assaults from commercial properties, keeping tenants and visitors safer.
“Every child deserves the best care possible and the second contract is for a K1 Hemisphere to be used at a pediatric healthcare clinic in Torrance, CA. Clinics for children must include a safe, comfortable experience for the entire family, from unique amenities – like Knightscope ASRs – to child-sized equipment, all focused on creating a trusted destination to care for California’s youth.”
Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information, visit the company’s website at www.knightscope.com.
NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
FingerMotion (NASDAQ: FNGR), a mobile services and data company, is responding to the Oct. 3, 2023, short seller report issued by Capybara Research, a short-selling research firm. According to the statement, FingerMotion management reviewed the report and believe that the report contains errors, unsupported speculations and inaccurate interpretations of events; management and the company’s board of directors are planning further review and examination of allegations and misinformation contained in the report. The company “will take whatever necessary and appropriate actions may be required to protect the interest of its shareholders,” the announcement stated. “The company is already in the process of identifying and engaging experts who can assist it in identifying the perpetrators behind this coordinated action. The company endeavors to provide full and accurate disclosure to investors and rebut any false claims that attempt to impair market confidence in FingerMotion’s business, operations and financial statements. The company is committed to maintaining the highest standards of corporate governance, as well as transparent and timely disclosure in compliance with the applicable rules and regulations of the United States Securities and Exchange Commission and the NASDAQ rules.” The announcement also noted that the company has filed the Form S-3 registration statement, which was declared effective by the SEC on Sept. 29, 2023.
FingerMotion is an evolving technology company with a core competency in mobile payment and recharge platform solutions in China. As the user base of its primary business continues to grow, the company is developing additional value-added technologies to market to its users. The vision of the company is to rapidly grow the user base through organic means and have this growth develop into an ecosystem of users with high engagement rates utilizing its innovative applications. Developing a highly engaged ecosystem of users would strategically position the company to onboard larger customer bases. FingerMotion eventually hopes to serve more than 1 billion users in the China market and expand the model to other regional markets. For more information about the company, please visit www.FingerMotion.com.
NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR
About ChineseWire
ChineseWire (“CW”) is a specialized communications platform with a focus on promising China-based companies that are listed in North America. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CW brings its clients unparalleled recognition and brand awareness. CW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the ChineseWire website applicable to all content provided by CW, wherever published or re-published: https://www.ChineseWire.com/Disclaimer
NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, today announced that it will present at the 8th Annual Dawson James Conference taking place at the Wyndam Grand Jupiter at Harbourside Place in Jupiter, Florida, on Thursday, Oct. 12, 2023. NextPlat Corp’s executive chairman and CEO Charles M. Fernandez will deliver the company’s presentation and conduct in-person, one-on-one meetings throughout the conference. Fernandez’s presentation is slated to begin at 11 a.m. ET in Preserve Ballroom C.
NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company intends to assist businesses in selling their goods online, domestically and internationally, allowing customers and partners to optimize their e-commerce presence and revenue. NextPlat currently operates an e-commerce communications division offering voice, data, tracking, and IoT products and services worldwide and pharmacy and healthcare data management services in the United States.
NOTE TO INVESTORS: The latest news and updates relating to NXPL are available in the company’s newsroom at https://ibn.fm/NXPL
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Mexico has become the United States’ leading international trading partner in recent months amid the country’s ongoing trade war with China
Coincidental with Mexico’s growth as a nearshore commercial trade partner, the port at Laredo, Texas has become the most lucrative hub for cross-border commerce, recording $28.1 billion during this year’s first quarter
Freight Technologies (aka Fr8Tech) is dedicated to aiding cross-border commerce through a suite of technological solutions targeting the relatively unorganized cross-border shipping and carrier industry
Fr8Tech’s flagship platform, Fr8App, draws on artificial intelligence and machine learning technology to help match loads optimally and monitor shipments from origin to final destination
The ongoing trade war between the United States and China is leading to a shift in international commerce sourcing that is manifest in changes to the volume of trade traffic at the United States’ shipping and transport gateways.
U.S. Census Bureau data analyzed by media organization WorldCity and in turn reported last month by FreightWaves.com (https://ibn.fm/wXWD5) indicates that Mexico has been the lead trading partner for the United States during five of the past six months, and that the shift toward nearshoring of…
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Genprex (NASDAQ: GNPX) is at the forefront of pioneering cancer treatments, and it’s making waves with remarkable advancements in lung cancer therapy. The company will be sharing compelling clinical and preclinical data at the prestigious 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15 at the Hynes Convention Center in Boston.
The Acclaim-1 Phase 1 study results have demonstrated the safety and efficacy of REQORSA(R) in combination with Tagrisso(R), bringing hope to patients with late-stage NSCLC. Moreover, preclinical studies have highlighted REQORSA(R)’s potential in combination with a checkpoint inhibitor to combat chemotherapy-resistant small cell lung cancer (“SCLC”).
Two simultaneous presentations will showcase the company’s advancements on October 12 from 12:30 pm – 4:00 pm ET. Alexander I. Spira, M.D., PhD, Virginia Cancer Specialists, Fairfax, VA will be presenting “Completion of Acclaim-1 dose escalation: Recommended Phase 2 dose of quaratusugene ozeplasmid gene therapy and osimertinib.”
Concurrently, Ismail Meraz, Ph.D., Senior Research Project Manager, The University of Texas MD Anderson Cancer Center will be presenting “TUSC2 immunogene therapy enhances checkpoint blockade through increased cytotoxic immune activation in chemo-resistant small cell lung cancer (SCLC) in humanized mice.”
Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its systemic, non-viral ONCOPREX(R) Nanoparticle Delivery System, which encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The company’s lead product candidate, REQORSA(R) (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (“NSCLC”) and small cell lung cancer (“SCLC”). Each of Genprex’s three lung cancer clinical programs has received a Fast Track Designation from the Food and Drug Administration (“FDA”), and its SCLC program has received an FDA Orphan Drug Designation. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an adeno-associated virus (“AAV”) vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-003 for type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. For more information, visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Scinai Immunotherapeutics (NASDAQ: SCNI) today announced that it will showcase its CDMO services at CPHI Barcelona, one of the international pharmaceutical industry’s premier trade shows, taking place Oct. 24 to 26. Scinai’s CDMO offers upstream and downstream process development and scale-up for protein-based drugs, analytical method development, and cGMP manufacturing including aseptic filling to biopharmaceutical and biotech clients. According to the announcement, several members of Scinai’s executive leadership team will be available to meet with potential partners and clients of the company’s end-to-end biologics CDMO service. Interested parties may request one-to-one meetings through the CPHI partnering platform, accessible to participants after registration at europe.cphi.com, or may email Scinai directly at [email protected]. In addition to CPHI Barcelona, Scinai will attend BIO-Europe in Munich, Germany (Nov. 6-8), and MIXiii Health-Tech.IL in Jerusalem, Israel (Nov. 7-8). Details are available on Scinai’s new website.
Scinai is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing and highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody (“NanoAb”) pipeline targeting diseases with large unmet medical needs. For more information, visit the company’s website at www.Scinai.com.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots and blue light emergency communication systems, has announced three new sales for its K1B Emergency Communications Systems. According to the update, the orders were placed by a college in Pennsylvania and two hospital systems – one in Illinois and one in Indiana.
The announcement reads, “Healthcare organizations across the U.S. have partnered with Knightscope for many years to make advancements in various critical areas of physical security and emergency communications while improving patient satisfaction. The adoption of such technologies is aiding healthcare organizations to maintain or increase their HCAHPS scores when following Knightscope’s recommendations outlined in a recent blog here.
“Colleges and universities are experiencing similar successes by staving off crime in our educational institutions by investing in a wide array of approaches that systematically create safe, healthy and supportive schools for all students. Improving the overall safety of everyone on campus results in better attendance, higher grades and a more enjoyable learning experience, all of which leads to a more productive society.”
Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information, visit the company’s website at www.knightscope.com.
NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
D-Wave’s (NYSE: QBTS) CEO Alan Baratz is the author of a recently published Fast Company opinion article that explores the vast possibilities of innovation as well as big tech giants’ track record of squashing technologies that they either don’t have the ability to create or missed the boat on. The piece, titled “POV: It’s time for big tech to stop stifling innovation,” delves into this concept while exploring ways that all companies, from startups to household names, can have a seat at the table and flourish on innovation.
“Most of us could do a better job at thinking critically and not blindly buying into the hype and promises of these large companies. In order to make informed decisions, it’s essential that we gather information from different sources—that represent different viewpoints—to validate products and their claims. Stay open to different possibilities: Don’t be afraid to engage with new technologies, pursue different proofs of concept, and deploy solutions once their value has been proven. This is where true innovation happens,” Baratz writes in the piece. “It’s easy to listen to what big tech says and take it as fact—it’s a lot harder to gather, analyze and validate data, and ask important questions.’”
D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers — and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s customers include Volkswagen, Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California, and Los Alamos National Laboratory. For more information, visit the company’s website at www.DWaveSys.com.
NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently reported results from its human oral nicotine study NIC-H22-1, comparing Lexaria’s DehydraTECH(TM)-nicotine tobacco-free pouch to world-leading brands ZYN(R) and on! “Using measurements to determine the median time required to reach comparable nicotine concentrations within the bloodstream (‘Tmax’), Lexaria exhibited higher levels of certain pleasurable effects over the competition. DehydraTECH also provided the lowest frequency of unwanted negative effects, including moderate to severe nausea, demonstrating benefits from Lexaria’s formulation,” a recent article reads. “We’ve always had an overwhelming determination and fierce conviction that we can make the world a better place and reduce the carnage caused by smoked cigarettes, and now we have human study data that demonstrates advantages of DehydraTECH-processed nicotine relative to the competitive landscape,” Lexaria CEO Chris Bunka is quoted as saying.
Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 36 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, will be participating at this month’s Emerging Growth Conference. The event is slated for Oct. 4–5, 2023. Knightscope CEO and chair William Santana Li is a featured presenter on the agenda.
According to the announcement, Santana will be presenting a fireside chat titled “AI Robots.” During his presentation, Santana will discuss the company’s new bond offering as well as Knightscope AI, autonomy and robotics, along with the company’s commitment to public safety. The presentation will also include a live Q&A portion. Santana’s presentation is scheduled to begin at 2 p.m. ET on Thursday, Oct. 5.
The Emerging Growth Conference is designed to be an ideal gathering for individual and institutional investors as well as advisors and analysts to have opportunities to interact with company executives. An archived version of Santana’s presentation will be available on the Emerging Growth Conference website and YouTube channel.
Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information about the company, please visit www.Knightscope.com.
NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
SenesTech, with its proprietary biological solution for efficiently and safely reducing rat populations without killing, represents a remarkable new path to clean cities, businesses, and households
According to pest industry figures, rats cause over $27 billion in damage to public and private infrastructure annually in the United States
ContraPest offers a unique solution for wastewater facilities because it is non-poisonous and comes in a variety of formats that can help control rat populations where other approaches fall short
SenesTech (NASDAQ: SNES), the rodent fertility control experts and the inventor of the only EPA-registered contraceptive for male and female rats, recently announced that its ContraPest(R) is being deployed in Washington and California through wastewater treatment facilities. Controlling rat infestations presents a unique challenge for wastewater treatment facilities because poisons cannot be introduced into the water supply, and ground-based stations may not be appropriate for many of the facilities.
“Municipalities and government entities comprise a broad and diverse customer base. We are continuously working with these customers, and the pest management professionals who service them, to understand their specific needs and to guide them as to how best to add ContraPest to their integrated…
NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
Scinai Immunotherapeutics, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, recently finalized a major rebrand, changing its corporate name from BiondVax Pharmaceuticals
The rebrand is part of a series of steps to better reflect the company’s new direction and new developments aimed at new scientific breakthroughs
Amir Reichman took over as CEO in March 2021 and together with the Board of Directors, began implementing a raft of changes aimed at redirecting the company’s focus and diversifying corporate risks
Scinai is developing a pipeline of novel NanoAbs, with its development pipeline including NanoAbs for the treatment of psoriasis, psoriatic arthritis, asthma, macular degeneration, and Hidradenitis Suppurativa
The company is intensifying its pipeline development, identifying additional opportunities, and developing novel solutions for large-market unmet needs in 2023 and beyond
When Amir Reichman took over the reins as CEO of the then-named BiondVax Pharmaceuticals in March 2021, he and the Board of Directors embarked on redefining the biotechnology company’s mission and vision. “Our new mission reflects an aspiration to focus on infectious diseases, which leverages [the company’s] core competencies, while ensuring fdiversification of our corporate risks through the establishment of a new, broad product and platform pipeline,” shared Reichman in his first letter to shareholders (https://ibn.fm/oyYwX).
Reichman expressed his intent to rejuvenate the company by implementing a strategy that would diversify the risk along four main axes, including building a pipeline of products for both prevention and treatment of infectious diseases and related illnesses; building a pipeline that would present…
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, is sharing a shareholder letter from Renovaro CEO Mark R. Dybul, MD. In the letter, Dybul provides information about the definitive agreement the company recently signed with artificial intelligence company GEDiCube. In the letter, Dybul noted that the two companies decided to combine in order to accelerate a shared mission to transform medicine and promote healthy longevity through the synergistic applications of advanced AI technology and pioneering biotherapeutics. Dybul noted that he anticipates serving as CEO of the combined company.
The letter notes that the combined company will bring together two innovative platforms in AI and biotherapeutics that will offer comprehensive solutions spanning early cancer detection, diagnostic insights and targeted immunotherapies. Renovaro’s expertise is an advanced immunotherapy platform focused initially on deadly solid tumor cancers that have seen only slightly improved survival rates while GEDiCube brings an award-winning AI technology that has already exhibited potential to detect lung cancer early with 95% accuracy by analyzing complex molecular data. “By joining forces, our two technology divisions will collaborate to push new boundaries in precision diagnostics and targeted treatments,” said Renovaro BioSciences CEO Mark R. Dybul, MD, in the press release. “At the same time, we will maintain nimble independent operations, allowing each platform to advance rapidly. I am excited to lead this combined company alongside our esteemed leadership team and board members, who offer unparalleled experience across AI, healthcare, and biotechnology. We share an ambitious vision to leverage AI to improve patient outcomes by detecting diseases sooner and matching treatments more precisely to the individual. We believe that the coming months will be exciting as we prepare to realize this combination’s potential and deliver on our commitment to shareholders.”
Renovaro BioSciences has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases. For more information about the company, visit www.RenovaroBio.com.
NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Lexaria’s patented DehydraTECH(TM)-processed CBD has shown its ability to lower blood pressure in patients over multiple weeks
This technology has also shown positive impacts in obese diabetic-conditioned animals from its DIAB-A22-1 pre-clinical study
The NIC-H22-1 human nicotine study also demonstrated a statistically significant difference to achieve maximum blood saturation
These results have demonstrated DehydraTECH’s potential while propping it to take advantage of vastly untapped markets with potential for growth in the coming years
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is steadily advancing its patented DehydraTECH(TM) technology for its growing range of applications, which include oral nicotine, hypertension, antivirals, human hormone therapy, diabetes and more. The progress achieved thus far has been the product of years of clinical and pre-clinical research, all of which reflect management’s confidence in the company’s direction and technology.
As of the three months ended May 31, 2023, the company had increased its research and development (“R&D”) expenses by 118% year-over-year, primarily focused on the execution of hypertension, oral nicotine, and diabetes studies (https://cnw.fm/WUofP). This devotion of a significant proportion of its…
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CBDWire
CBDWire (“CBDW”) is a specialized communications platform with a focus on CBD related news and updates in the cannabidiol (“CBD”) sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled recognition and brand awareness.
CBDW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CBDWire, text “CBDWire” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer
Autism Spectrum Disorder (“ASD”) has seen a staggering fourfold increase in the United States over the past two decades
PaxMedica proudly stands as the sole publicly traded U.S. company singularly dedicated to addressing the challenges posed by Autism
Our pioneering lead product, PAX-101, has shown significant promise in alleviating core Autism symptoms during early trials
In 2024, we’re poised to submit a New Drug Application (“NDA”) for PAX-101 to treat Human African Trypanosomiasis (“HAT”), a rare disease also known as African Sleeping Sickness, as part of the Neglected Rare Tropical Disease Program
With NDA approval, we anticipate the potential to secure a valuable Priority Review Voucher (“PRV”) that could expedite our journey toward FDA recognition for Autism treatment
Vigorous preparations are underway for clinical trials of PAX-101 in Autism, marking a significant step forward in our mission
In a powerful and informative video message, PaxMedica’s (NASDAQ: PXMD) Chairman and CEO, Howard Weisman, shares a progress report on the critical work being done to address the rising prevalence of Autism Spectrum Disorder (“ASD”) in the United States. This disorder has seen a fourfold increase over the past two decades, underscoring the urgency of PaxMedica’s mission.
PaxMedica stands alone as the only publicly traded company in the U.S. with an unwavering focus on ASD. Weisman highlights the dedication and commitment of the entire PaxMedica team to confront the…
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, is continuing to add to its client roster. This time the company has inked deals with its first-ever ASR clients in Louisiana: two casinos, one located in Shreveport and the other in Bossier City.
According to the announcement, the two K5 ASR contracts have been executed as part of a larger agreement Knightscope received earlier this month. The contracts call for the two casinos to each receive a K5 robot. These two new ASRs bring the total robots under the contract to five, with the other robots being deployed to Las Vegas; Council Bluffs, Iowa; and Aurora, Illinois.
The ASRs at each of these locations are used to “greet guests with a friendly voice while also providing additional eyes and ears for the large human security team,” stated Knightscope in the press release. “Robots also offer a two-way communication system to enhance the safety of visitors and workers.”
Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information about the company, please visit www.Knightscope.com.
NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP
About AINewsWire
AINewsWire (“AINW”) is a specialized communications platform with a focus on the latest advancements in artificial intelligence (“AI”), including the technologies, trends and trailblazers driving innovation forward. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, AINW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, AINW brings its clients unparalleled recognition and brand awareness.
AINW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from AINewsWire, text “AI” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the AINewsWire website applicable to all content provided by AINW, wherever published or re-published: https://www.AINewsWire.com/Disclaimer
InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, is reporting on the financial results for its fiscal year 2023, the period ending June 30, 2023. In addition, the company provided a status update on its pharmaceutical drug-development programs as well as the commercial segment for BayMedica LLC, its wholly owned subsidiary. Highlights of the report include total sales for subsidiary BayMedica of rare cannabinoids in the health and wellness sector reaching $4.1 million, an increase of 280% over the previous fiscal year and $2.3 million in revenue for the three months ended June 30, 2023, a quarter-over-quarter increase of 123%; cash, cash equivalents and short-term investments reached $9 million; completion of the phase 2 clinical trial studying the treatment of Epidermolysis Bullosa (“EB”); the launch of the INM-900 series preclinical program targeting the treatment of neurodegenerative diseases, including Alzheimer’s, Huntington’s and Parkinson’s disease; and the publication of a peer-reviewed study showing the anti-inflammatory potential of rare cannabinoids in skin conditions.
In addition, the company reported a net loss for the fiscal year of $7.9 million, a decrease from the $18.6 million loss reported the previous year. “In fiscal year 2023, the company’s wholly owned subsidiary, BayMedica, achieved substantial revenue growth via the supply of rare cannabinoids as ingredients to the health and wellness sector,” said InMed Pharmaceuticals CEO Eric A. Adams in the press release. “In the January to June timeframe, BayMedica experienced substantial growth, as evidenced by two consecutive quarters of significant revenue increases. While we expect some fluctuations in revenue as ordering patterns in this developing market still mature, we remain optimistic about the long-term growth potential in the rare cannabinoids sector as the business dynamics and commercial opportunities continue to mature. Additionally, we continue to advance our pharmaceutical pipeline using rare cannabinoids for potential therapeutic applications in dermatology, ocular and neurodegenerative disease.”
InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. The company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, please visit www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has inked a deal with GEDi Cube Intl Ltd. The agreement is to combine the two companies with GEDi Cube becoming a wholly owned subsidiary of Renovaro in a stock-for-stock acquisition. The combined company would focus on accelerating precision and personalized medicine for longevity powered by mutually reinforcing artificial intelligence (“AI”) and biotechnology platforms to enable early diagnosis, better targeted treatments and drug discovery. GEDi Cube is an artificial intelligence medical technology company. According to the announcement, the newly formed company would have a unique advantage: Renovaro Biosciences’ preclinical and clinical trial data could be leveraged to accelerate GEDi Cube’s AI capabilities that, in turn, could help to accelerate Renovaro’s development of potential new therapies. “We believe GEDi Cube’s AI technology will enhance and accelerate the development of treatments we are currently pursuing as well as power the discovery of new therapeutic approaches for cancer and other diseases,” said Renovaro Biosciences CEO Dr. Mark Dybul in the press release. “The combined company will have independent operating divisions that will allow each technology to move as quickly as possible to commercialization while the collaboration between divisions will aim to drive new advances in both AI and medicine.”
Renovaro BioSciences has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases. For more information about the company, visit www.RenovaroBio.com.
NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
On September 28, 2023, Clene Inc. made an exciting announcement regarding their groundbreaking research on the investigational drug CNM-Au8. In a scientific paper published in the esteemed journal Small, Clene Inc. revealed the catalytic mechanism of action behind the therapeutic properties of CNM-Au8.
The study showcased the remarkable neuroprotective abilities of CNM-Au8, attributing its success to its unique catalytic activity. When exposed to toxins that typically lead to neuronal death, CNM-Au8 treatment exhibited a remarkable ability to promote cell survival and preserve the intricate network of…
The IW website may contain Third-Party Content articles and other content submitted by third parties, including articles submitted through the IW Premium Partnership Program. All opinions, statements and representations expressed by such third parties are theirs alone and do not express or represent the views and opinions of IW or its affiliates and owners. Content created by third parties is the sole responsibility of such third parties, and IW does not endorse, guarantee or make representations concerning the accuracy and completeness of any third-party content. You acknowledge that by IW providing you with this internet portal that makes accessible to you the ability to view third party content through the IW site, IW does not undertake any obligation to you as a reader of such content or assume any liability relating to such third-party content. IW expressly disclaims liability relating to such third-party content. IW and its members, affiliates, successors, assigns, officers, directors, and partners assume no responsibility or liability that may arise from the third-party content, including, but not limited to, responsibility or liability for claims for defamation, libel, slander, infringement, invasion of privacy and publicity rights, fraud, or misrepresentation, or an private right of action under the federal securities laws of the United States or common law. Notwithstanding the foregoing, IW reserves the right to remove third-party content at any time in its sole discretion. By viewing this third-party content, you acknowledge that you have viewed, read fully, accepted and agreed to all terms of the Disclaimer at https://www.investorwire.com/disclaimer.
The disclaimers on the IW website are applicable to all content provided by IW, wherever published or re-published are at: https://www.investorwire.com/disclaimer
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
SenesTech (NASDAQ: SNES), animal pest fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, has selected IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its corporate communications initiatives. According to the announcement, IBN will leverage its suite of communications solutions to generate greater awareness of SenesTech, a company focused on developing effective pest-control solutions that are grounded in science and proven through field testing. IBN brings an array of communication channels to the new partnership, including an investor-based distribution network of more than 5,000 key syndication outlets, numerous newsletters and social media channels, and targeted wire services as well as blogs and other powerful outreach tools.
“SenesTech’s ContraPest(R) has already been shown to reduce rat activity over 90% when added to an existing integrated pest-management program, and the company is committed to making it even more accessible to its growing list of clients,” stated IBN director of operations Chris Johnson in the press release. “We’re excited to customize our comprehensive suite of corporate communications solutions for SenesTech as it rapidly approaches the anticipated release of a revolutionary soft bait formulation, which is expected to greatly expand its adoption among big box retailers, key e-commerce channels and leading industry pest management professionals.”
SenesTech is the expert in animal pest fertility control. The company’s passion is to create a healthy environment by better controlling rat pest populations. The company keeps an inescapable truth in mind: two rats and their descendants can be responsible for the birth of up to 15,000 pups after a year. SenesTech invented ContraPest, the only U.S. EPA-registered contraceptive for male and female rats. ContraPest fits seamlessly into all integrated pest-management programs, greatly improving the overall goal of effective rat management. The company strives for clean cities, efficient businesses and happy households — with a product that was designed to be effective and sustainable without killing rats. SenesTech is committed to improving the health of the world by humanely managing animal populations through fertility control. For more information about the company, please visit www.SenesTech.com.
NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has delivered the first 10 class 3 EV Cab Chassis Truck to Randy Marion Automotive Group; the vehicles are invoiced at $630,000. According to the announcement, these first 10 vehicles are the initial shipment of an order for 1,000 class 3 vehicles, an order worth $63 million; the order was placed in May 2023. The company anticipates delivering an additional 150 EVs to Randy Marion by the end of 2023, with the remainder of the 1,000-vehicle order slated for delivery throughout 2024. Calling the delivery a “watershed moment” for the company, the announcement noted that the Mullen THREE class 3 EV truck was the first vehicle produced, assembled and now delivered by the company. The Mullen THREE is produced in the company’s Tunica, Mississippi, facility, which houses Mullen’s commercial vehicle assembly for both Class 1 EV Cargo Vans and Class 3 EV Cab Chassis Trucks. “This is a significant point in our evolution as we shift the company from engineering development and engineering approvals to production and vehicle deliveries for our customers,” said Mullen CEO and chair David Michery in the press release. “As the Class 3 line is fully operational, production will be increasing month-to-month throughout the next year.”
Mullen Automotive is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover; the Mullen I-GO Commercial Urban Delivery EV; the Mullen commercial class 1–3 EVs; and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and class 4–6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of all Electric Last Mile Solutions (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. To learn more about the company, visit www.MullenUSA.com.
NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN
About GreenCarStocks
GreenCarStocks (“GCS”) is a specialized communications platform with a focus on electric vehicles (“EVs”) and the green energy sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled recognition and brand awareness. GCS is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from GreenCarStocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the GreenCarStocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
